CN1202523A - 减毒的活胸膜肺炎放线杆菌 - Google Patents
减毒的活胸膜肺炎放线杆菌 Download PDFInfo
- Publication number
- CN1202523A CN1202523A CN98109848A CN98109848A CN1202523A CN 1202523 A CN1202523 A CN 1202523A CN 98109848 A CN98109848 A CN 98109848A CN 98109848 A CN98109848 A CN 98109848A CN 1202523 A CN1202523 A CN 1202523A
- Authority
- CN
- China
- Prior art keywords
- asp
- leu
- gly
- asn
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 title claims abstract description 95
- 241000894006 Bacteria Species 0.000 title claims abstract description 65
- 230000002238 attenuated effect Effects 0.000 title abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 107
- 239000003053 toxin Substances 0.000 claims abstract description 99
- 231100000765 toxin Toxicity 0.000 claims abstract description 73
- 229960005486 vaccine Drugs 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 35
- 241001465754 Metazoa Species 0.000 claims abstract description 19
- 208000015181 infectious disease Diseases 0.000 claims abstract description 18
- 238000012360 testing method Methods 0.000 claims abstract description 18
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 16
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 6
- 238000003745 diagnosis Methods 0.000 claims abstract 2
- 230000001580 bacterial effect Effects 0.000 claims description 46
- 230000014509 gene expression Effects 0.000 claims description 27
- 210000002966 serum Anatomy 0.000 claims description 26
- 241000282898 Sus scrofa Species 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 241000606731 Actinobacillus suis Species 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 238000011081 inoculation Methods 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 238000013467 fragmentation Methods 0.000 claims description 10
- 238000006062 fragmentation reaction Methods 0.000 claims description 10
- 230000002068 genetic effect Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 229940031567 attenuated vaccine Drugs 0.000 claims description 8
- 230000008034 disappearance Effects 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 241000588779 Bordetella bronchiseptica Species 0.000 claims description 4
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 4
- 241000606807 Glaesserella parasuis Species 0.000 claims description 4
- 241000702670 Rotavirus Species 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 4
- 241000725681 Swine influenza virus Species 0.000 claims description 4
- 241000711484 Transmissible gastroenteritis virus Species 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000012153 swine disease Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 823
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 489
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 487
- 102220023258 rs387907548 Human genes 0.000 description 85
- 108700012359 toxins Proteins 0.000 description 65
- 102220023257 rs387907546 Human genes 0.000 description 42
- 102220369445 c.668T>C Human genes 0.000 description 34
- 102220023256 rs387907547 Human genes 0.000 description 30
- 102220369447 c.1352G>A Human genes 0.000 description 27
- 241000606750 Actinobacillus Species 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 230000036039 immunity Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 102220004457 rs11567847 Human genes 0.000 description 16
- 230000004927 fusion Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 11
- 230000029087 digestion Effects 0.000 description 9
- 229920002704 polyhistidine Polymers 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 230000002588 toxic effect Effects 0.000 description 9
- 241000606729 Actinobacillus equuli Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 102220369446 c.1274G>A Human genes 0.000 description 6
- 239000013611 chromosomal DNA Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 230000008676 import Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 239000000304 virulence factor Substances 0.000 description 5
- 230000007923 virulence factor Effects 0.000 description 5
- 241000606801 Actinobacillus lignieresii Species 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 101710116435 Outer membrane protein Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000606860 Pasteurella Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000122975 Actinobacillus pleuropneumoniae serovar 1 Species 0.000 description 2
- QQEWINYJRFBLNN-DLOVCJGASA-N Asn-Ala-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QQEWINYJRFBLNN-DLOVCJGASA-N 0.000 description 2
- WOPJVEMFXYHZEE-SRVKXCTJSA-N Asp-Phe-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WOPJVEMFXYHZEE-SRVKXCTJSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- SBYVDRJAXWSXQL-AVGNSLFASA-N Glu-Asn-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SBYVDRJAXWSXQL-AVGNSLFASA-N 0.000 description 2
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 2
- HKSNHPVETYYJBK-LAEOZQHASA-N Gly-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CN HKSNHPVETYYJBK-LAEOZQHASA-N 0.000 description 2
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- MLSUZXHSNRBDCI-CYDGBPFRSA-N Ile-Pro-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O)N MLSUZXHSNRBDCI-CYDGBPFRSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- HWMZUBUEOYAQSC-DCAQKATOSA-N Lys-Gln-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O HWMZUBUEOYAQSC-DCAQKATOSA-N 0.000 description 2
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 2
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 2
- LKJCABTUFGTPPY-HJGDQZAQSA-N Thr-Pro-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O LKJCABTUFGTPPY-HJGDQZAQSA-N 0.000 description 2
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 2
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 101100206919 Arabidopsis thaliana TL29 gene Proteins 0.000 description 1
- YKZJPIPFKGYHKY-DCAQKATOSA-N Arg-Leu-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKZJPIPFKGYHKY-DCAQKATOSA-N 0.000 description 1
- RRUWMFBLFLUZSI-LPEHRKFASA-N Asp-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N RRUWMFBLFLUZSI-LPEHRKFASA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- IXFVOPOHSRKJNG-LAEOZQHASA-N Gln-Asp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IXFVOPOHSRKJNG-LAEOZQHASA-N 0.000 description 1
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 101150098499 III gene Proteins 0.000 description 1
- FVEWRQXNISSYFO-ZPFDUUQYSA-N Ile-Arg-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FVEWRQXNISSYFO-ZPFDUUQYSA-N 0.000 description 1
- CCHSQWLCOOZREA-GMOBBJLQSA-N Ile-Asp-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N CCHSQWLCOOZREA-GMOBBJLQSA-N 0.000 description 1
- KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 1
- ZNOBVZFCHNHKHA-KBIXCLLPSA-N Ile-Ser-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZNOBVZFCHNHKHA-KBIXCLLPSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- 241001071864 Lethrinus laticaudis Species 0.000 description 1
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 1
- URHJPNHRQMQGOZ-RHYQMDGZSA-N Leu-Thr-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O URHJPNHRQMQGOZ-RHYQMDGZSA-N 0.000 description 1
- RPWTZTBIFGENIA-VOAKCMCISA-N Lys-Thr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RPWTZTBIFGENIA-VOAKCMCISA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 101100379386 Oryza sativa subsp. japonica APX4 gene Proteins 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101100038645 Streptomyces griseus rppA gene Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 1
- NIEWSKWFURSECR-FOHZUACHSA-N Thr-Gly-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NIEWSKWFURSECR-FOHZUACHSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- NXRGXTBPMOGFID-CFMVVWHZSA-N Tyr-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O NXRGXTBPMOGFID-CFMVVWHZSA-N 0.000 description 1
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229940049547 paraxin Drugs 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及在apxⅣ基因中具有突变从而不能产生有功能的ApxⅣ毒素的胸膜肺炎放线杆菌属活减毒菌。本发明也涉及制备这种细菌的方法。包括这种细菌的疫苗及用于制备该疫苗的方法也是本发明的部分。本发明进一步涉及包括ApxⅣ毒素的亚单位疫苗,制备该疫苗的方法及用于保护动物免受胸膜肺炎放线杆菌属细菌感染的方法。此外,本发明涉及apxⅣ基因的启动子。最后,本发明涉及用于选择性诊断胸膜肺炎放线杆菌感染的诊断测试及区分胸膜肺炎放线杆菌野生菌株与疫苗菌株的诊断测试。
Description
本发明涉及在编码毒素基因中具有突变的减毒活胸膜肺炎放线杆菌,用于制备该细菌的方法,包括该细菌的疫苗,制备这种疫苗的方法,包括毒素的疫苗,制造这种疫苗的方法以及用于保护动物免受胸膜肺炎放线杆菌感染的方法。
放线杆菌属的细菌均产生所谓的RTX-毒素。(RTX代表毒素中的重复)。
正是由于这些RTX-毒素的存在才高度地促成了这些细菌的病原性特征。
RTX-毒素已由Braun等进行了广泛综述。(微生物学关键综述18(2):115-158(1991))。革兰氏阴性菌株的RTX-毒素也已由Welch,R.A.(分子微生物学5/3:521-528(1991))和Welch等(感染源和疾病4:254-272(1995))加以综述。
所有已知的RTX-毒素显示一定种类的细胞毒或溶细胞活性。然而依据毒素和酰化的差异,靶细胞和宿主特异性各有不同(McWhinney等;细菌学杂志174:291-297(1992)和Hackett等;生物化学杂志270:20250-20253(1995))。由于靶细胞的不同,RTX-毒素家族的多种毒素称为如溶血素、溶细胞素或细胞毒素。
放线杆菌属包括许多不同种,特别是胸膜肺炎放线杆菌、体放线放线杆菌、猪放线杆菌、罗氏放线杆菌、马驹放线杆菌(A.equuli)和李氏放线杆菌(A.Lignieresi)。
胸膜肺炎放线杆菌产生血清型依赖性RTX-毒素,其对猪、马、牛和人类红细胞、兔和猪嗜中性细胞和猪肺泡巨噬细胞是细胞毒性/溶细胞性的(Rosendel等;美国兽医研究杂志,49:1053-1058(1998),MaudsleyJ.R.和Kadis S;加拿大微生物学杂志,32:801-805(1986),Frey.J和Nicolet J;感染与免疫,56:2570-2575(1988),Bendixon等;感染与免疫,33:673-676(1981),Kamp,E.M.和VanLeengoed,L.A.M.G.;临床微生物学杂志,27:1187-1191(1989))。
猪中放线杆菌的感染,由于小猪的急性致死和大龄动物体重净增的下降而导致养猪业中严重的经济损失。
革兰氏阴性细菌中涉及RTX-毒素合成,激活和运输的操纵子的遗传结构最近已由Coote,J.G加以综述(FEMS微生物学综述88:137-162(1992))。Frey已在细菌蛋白毒素,Zbl Bakt增刊,24,p.322-,Freer等.(编),Gustaf Fischer,Stuttgart,Jena,纽约,1994中对胸膜肺炎放线杆菌中的已知三种RTX-毒素进行了具体的综述。
在胸膜肺炎放线杆菌中,此种RTX-操纵子含有4个基因:实际的毒素-基因(A),激活基因(C)和2个编码涉及毒素分泌至周围介质蛋白的基因(B和D)。毒素基因(A)的初级翻译产物是无毒性的蛋白,其中的毒素活性由激活基因(C)产物所激活。
直到最近,认为只有具有上述遗传结构或至少具有毒素-基因(A)及激活基因(C)的三种RTX-毒素才存在于放线杆菌中。
这三种RTX-毒素,ApxI、Apx-II和Apx-III分别具有显著的溶血活性(ApxI)、温和的溶血活性(Apx-II)或巨噬细胞的细胞毒活性(Apx-III)。
各种毒素的活性以不同的血清型相当随机地划分。存在四种亚型:
由血清型1,5,9和11所代表的亚型A,产生ApxI和Apx-II,
由血清型2,3,4,6和8所代表的亚型B,产生
Apx-II和Apx-III,
由血清型10所代表的亚型C,仅产生ApxI,
由血清型7和12所代表的亚型D,仅产生Apx-II,
已知,ApxI、-II和-III是抗胸膜肺炎放线杆菌感染的一般疫苗中的必需成分:不包括至少ApxI、-II和III的疫苗将不提供对所有胸膜肺炎放线杆菌血清型的保护。同样,不包括至少一种特异血清型Apx-毒素的疫苗将甚至不会诱导对单-血清型的保护。
较早时期已描述了基于体外合成,丧失其毒性的胸膜肺炎放线杆菌RTX-毒素的亚单位疫苗,如在欧洲专利EP NO.0354.628中所述,其中公开了基于胸膜肺炎放线杆菌溶血素和细胞毒素的亚单位疫苗,并且在欧洲专利EP NO.0453.024中所述,其中公开了基于溶血素、细胞毒素和外膜蛋白的胸膜肺炎放线杆菌亚单位疫苗。
然而对亚单位疫苗来说一般具有4个重要的不足:
·为了充分地激活免疫系统需要大量的免疫原性材料。
·通常仅B-细胞免疫被激活。
·几种保护性抗原仅在体内被激活,且因此不能够以亚单位疫苗形式存在。
·活的病原性细菌具有许多重要的免疫原性分子,如外膜蛋白和荚膜蛋白,它们均对于保护至关重要且因此被包括进有效的亚单位疫苗中。
仅次于上述第1和第2点,尤其是第4点的明显问题使得难以制备有效的亚单位疫苗。
这由例如在上述欧洲专利EP NO.0.453.024中公开的胸膜肺炎放线杆菌亚单位疫苗加以说明,其中4种不同的亚单位(三种RTX-毒素和外膜蛋白)结合于一种疫苗中。
很显然,为了克服抗Pasteurellaeeae感染亚单位疫苗的不足,一种活的减毒疫苗将是高度需要的。
活减毒疫苗具有下面的优势:
其可用低剂量施用(其是自我复制的)
其密切模拟天然/野生-型感染
其同时提供所有可能的免疫学重要的抗原。不过,尽管明显的优势,本发明之前还没有商业上可得到的基于胸膜肺炎放线杆菌的活疫苗。其原因在于下面似是而非的论点:如前述,Apx-I、-II和-III均是抗胸膜肺炎放线杆菌感染普通疫苗的必需成分。因此活疫苗必需产生这三种RTX-毒素。然而这三种RTX-毒素是所有放线杆菌种类中强有力的毒性因子(见,如Coote,J.G.;FEMS微生物学综述88:137-162(1992)),Tascon等.;分子微生物学,14:207-216(1994),Jansen等.;感染与免疫.63:27-37(1995))。
为了减弱活App菌株的毒力而对RTX-毒素的缺失在技术上是可行的,但其没有提供解决问题的途径:由于它们不再在宿主中诱导对胸膜肺炎放线杆菌溶血/细胞毒活性的免疫性,故这种RTX-阴性菌株作为活减毒疫苗菌株将是无用的。
然而到现在,尽管在诱导免疫性中是重要的,但在建立免疫性中较ApxI、-II和-III是次要的毒力因子还是未知的。
因此,在App基因组中具有这样的位点是高度必要的,即该位点当被修饰时有利于毒力且因此导致减毒的App菌株,而同时,尽管其在激发免疫性中是有用的,但从疫苗观点来看是必不可少的。然而这样的位点目前还是未知的。此外,如果这样的位点将普遍存在于所有的App菌株中而不是局限于某些血清型中,该位点是高度必要的。那么这样的位点将通过相同位点的缺失允许对所有不同的血清型减毒。
提供普遍存在于无论什么血清型的所有胸膜肺炎放线杆菌菌株中的这种减毒位点是本发明的目的之一。
最近,在胸膜肺炎放线杆菌血清型1菌株中发现了一种新的基因(论文T.J.Anderson Nov.1995)。
尽管该基因不象已知的放线杆菌的ApxI、-II和-III基因,但其与已知的脑膜炎奈氏球菌的RTX-毒素具有相似性,正是由于此原因将其命名为RTX-基因apxIV。然而该基因几乎在所有的方面均与上述存在于各种放线杆菌科的不同种中的三种已知RTX-毒素基因apxI、-II和-III不同。首先,基因组结构完全不同。其次,没有如同发现于已知Apx-毒素的激活机制。第三,在那时没有特异性的体内溶血或细胞毒活性可归结于该基因或其可能的基因产物。
现已惊奇地发现该基因与三种已知的RTX-基因完全不同,无论其什么血清型存在于胸膜肺炎放线杆菌的所有种类中。这通过探针杂交加以测定,该探针包括apxIV编码序列,此序列中具有实施例6和7中所述所有血清型胸膜肺炎放线杆菌的DNA限制性片段。出乎意料的是现已发现,虽然apxIV缺失突变体是存活的,但与其具有apxIV的母本菌株相比,它们毒性较小。
因此,已确定该基因产物,ApxIV毒素是所有胸膜肺炎放线杆菌菌株中的毒力因子。这是个出乎意料的结论。因为到目前为止,根本没有什么效应,更不用说可能影响毒力的效应被归结于该基因的体内产物。实际上,直到现在无论如何甚至还没有该基因在胸膜肺炎放线杆菌体内或体外表达的证据。因此以下的发现是本发明的优点之一:
·apxIV基因存在于任何血清型的所有胸膜肺炎放线杆菌菌株中;
·apxIV基因产物是所有胸膜肺炎放线杆菌血清型中的毒力因子,
·具有apxIV基因缺失的胸膜肺炎放线杆菌菌株仍然是存活的但具有降低的毒力而没有显著减弱该菌株的免疫原性,
因此,本发明首次提供不产生有功能ApxIV毒素的胸膜肺炎放线杆菌活减毒细菌。
有功能的ApxIV毒素被认为是这样的一种蛋白:即其具有在野生型细菌中表达ApxIV毒素的所有特征,并且以野生型水平表达。因此,无功能的ApxIV毒素被认为是这样的一种毒素:即其缺乏在野生型细菌中表达ApxIV毒素的部分或所有特征,并且/或者以不足以获得ApxIV毒素野生型效应的水平表达。
产生ApxIV毒素能力的丧失可,例如是由于编码ApxIV毒素编码序列中的修饰。其也可是由于,例如,已知涉及apxIV基因转录的区域,如启动子区域的修饰或由于涉及翻译区域,如核糖体结合位点的修饰。
apxIV基因的整体结构列于图1中。
该图中,ApxIV毒素特征性的同向重复区由阴影框(dashed box)表示,而也是ApxIV特异的富含-甘氨酸的非肽(nonapeptide)区由黑箭头表示。该重复区发现于ApxIV的C-末端部分。这些鉴别性特征存在于所有的胸膜肺炎放线杆菌血清型中。两种血清型的核苷酸序列和氨基酸序列列于SEQ.ID NO.1-4中。SEQ.ID.NO.1显示了App血清型1apxIV基因的核酸序列,且SEQ.ID.NO.2显示了血清型1ApxIV毒素的相应氨基酸序列。SEQ.ID.NO.3显示了App血清型3apxIV基因的核苷酸序列,而SEQ.ID.NO.4显示了血清型3ApxIV毒素的相应氨基酸序列。图2显示各种胸膜肺炎放线杆菌血清型的Apx-毒素之间的氨基酸水平,特别位于N-末端的650个氨基酸具有相当高水平的保守性。这也是apxIV基因的异常特性。从图1中显而易见,根据血清型的不同,位于该毒素C-末端重复数目的差异可能发生。此差异解释了获自各种血清型基因及编码毒素大小的差异。
甚至在分离自相同血清型的胸膜肺炎放线杆菌不同分离物的apxIV基因之间可能有某些核苷酸序列的差异。这是由于本领域众所周知的存在于所有有机体中的自然变异。在由apxIV基因编码的ApxIV毒素中某些氨基酸由其它血清型ApxIV毒素中的别的氨基酸所替代是可能的,然而该多肽功能没有改变。例如,在某一位点含有Asp的多肽和其相应位点含有Asn的变异体仍然具有相同的特性。其中的氨基酸由功能类似氨基酸所替代的方法称为功能性替换。此时的变异体蛋白称为功能性变异体。另一种变异的原因是遗传密码简并现象。简言之,其意思为,例如氨基酸谷氨酸由GAT和GAA所编码。除了Met和Trp以外,此现象适用于所有的氨基酸。因此,很明显,例如本发明给出的血清型1ApxIV毒素可不仅由SEQ ID NO:1中的核苷酸序列所编码而且也可由很多种其它序列所编码,所有的仍然得到相同或功能相同的多肽。
因此,编码与ApxIV毒素功能相当多肽的变异apxIV序列属于本发明的范围之内。
根据本发明的活减毒细菌可以几种方式获得。获得该菌一种可能的方式是通过经典方法的途径,如以诱变剂如碱基类似物处理野生型胸膜肺炎放线杆菌,以紫外光处理或温度处理细菌。不产生有功能ApxIV毒素的菌株不诱导或以较小程度诱导抗ApxIV毒素抗体,且因此可容易地在动物测试中加以筛选。必需的抗血清可按下面实施例3中描述获得。另一种可能性是用重组DNA-技术有意识地向编码ApxIV毒素的基因中导入详细定义的突变。这样的突变可以是插入、缺失、一个核苷酸被另一个所替代或其组合,唯一的条件是该突变基因不再编码有功能的ApxIV毒素。可容易地看出,尤其是在开放阅读框中导入终止密码子的突变,或导致开放阅读框中移码的突变很适于获得不再编码有功能ApxIV毒素的菌株。这种突变可通过,例如,用Clontech销售的Transformer试剂盒的体外定点诱变方法加以完成。许多其它标准的重组DNA技术如以限制性酶消化基因,然后以内切核酸酶处理和重新连接同样是可用的。
因此,在优选的方式中,本发明的该实施方案涉及其中编码ApxIV毒素的基因包括突变的活减毒细菌。
包括apxIV基因片段或甚至整个基因缺失,或异源DNA-片段插入的详细定义的突变,与经典诱导的突变相比,具有这样的优势:即它们将不回复到野生型状况。
因此,在更为优选的方式中,本发明的该实施方案指其中编码ApxIV毒素的基因包括插入和/或缺失的活减毒细菌。
如果现将大量的疫苗施于猪中,只要是为了降低接种费用的原因,很明显几种疫苗的联合施用将会是合乎需要的。因此,使用活体减毒疫苗菌株作为编码选自其它病原性微生物或病毒抗原的异源基因的重组载体是很有吸引力的。施用这样的重组载体具有这样的优势,即施用该载体后,诱导出同时抗两种或更多种疾病的免疫性。因为编码ApxIV毒素的基因可用作这样异源基因的插入位点,所以根据本发明的活减毒细菌提供了异源基因很适宜的载体。ApxIV基因用作插入位点具有这样的优势:即apxIV基因被同时失活,并且新导入的异源基因可根据同源的胸膜肺炎放线杆菌基因来表达。这种重组载体的构建可用标准的分子生物学技术如同源重组按常规地加以完成。因此,在甚至更为优选的实施方案中,本发明涉及这样的活减毒的胸膜肺炎放线杆菌:即其不产生有功能的ApxIV毒素,并且其中有异源基因插入到ApxIV基因中。如上述,这样的异源基因可以是例如,编码选自其它病原微生物或病毒抗原的基因。另一种可能性是插入编码涉及激发免疫系统的蛋白,如白细胞介素或干扰素的基因。
在本发明更为优选的形式中,异源基因编码一个或更多个选自以下类群的抗原,包括猪生殖呼吸综合症(PRRS)病毒、假狂犬病毒、猪流感病毒、猪细小病毒、传染性胃肠炎病毒(Transmissible Gastroenteritisvires)、轮状病毒、大肠杆菌、猪丹毒丝菌、多杀巴斯德氏菌、支气管炎博德特氏菌、副猪嗜血菌及猪链球菌。
然而在重组载体中异源基因的表达有严重的潜在危险:已知这几种蛋白如果在异源菌中表达是有毒的。因此,编码该蛋白的基因决不可导入异源载体中,因为由于表达一定量异源基因,故成功的重组体将会最终死亡。流感嗜血杆菌的P-2蛋白,仅列举一个实施例,可简单地不在大肠杆菌中表达(Munson等,感染与免疫57:88-94(1989))。本发明的目标之一是提供没有此缺点的重组活载体。已意外发现,尽管apxIV基因在体内有效表达(见实施例5),但是其在体外不表达(见实施例4)。这是从未能在体外培养的胸膜肺炎放线杆菌培养物中显示出ApxIV毒素的存在得出的。这意味着ApxIV的表达依赖于其中培养有胸膜肺炎放线杆菌外在环境来开启和关闭。该特征较已知的活重组载体提供了出乎预料的优势:如果异源基因的表达受apxIV启动子控制,那么无论插入什么异源基因,根据本发明的胸膜肺炎放线杆菌活减毒载体可在体外培养至高密度,因为外源基因在这些条件下将不表达。施用许多细菌至宿主以后,异源基因的表达将开始且在复制期间或细菌死后的某个时间,其将是宿主的免疫系统可利用的。可通过,例如,用异源基因的编码区替代apxIV基因的编码序列而将待表达的异源基因有功能地连接到apxIV启动子上。替代整个apxIV基因是不必要的:以包括其终止密码子的异源基因编码区替代ApxIV的ATG密码子就已足够。通过建立融合构建体在apxIV启动子影响下表达异源基因也是可能的。这可通过在具有apxIV ATG密码子下游的apxIV阅读框的框架中插入异源基因加以完成。
词语“有功能地连接到apxIV启动子上”意思为异源基因的转录在apxIV启动子处起始。
不用说,插入异源基因的每个位置,其中的异源基因有功能地连接到apxIV启动子上,存在于本发明的范围之内。
因此,该实施方案最为优选的形式涉及本发明的活减毒细菌,其中带有有功能地连接到apxIV启动子区域上的异源基因。
天然apxIV启动子是个可开关的启动子,其在体外关闭且在体内打开,该惊人的发现使该启动子成为其天然宿主中和作为其它细菌的异源启动子很通用的表达工具。当用作其它细菌中的异源启动子时,包括该启动子的DNA可从其宿主中分离并转入除胸膜肺炎放线杆菌以外的细菌中。
现在易行的另一种选择是克隆数拷贝的apxIV启动子,其中每种控制着另一种基因的表达。这虽然能够在宿主菌胸膜肺炎放线杆菌中加以完成,但该多拷贝原理同样适用于其它细菌。如上述,该启动子可用于在体内选择性地表达一种或多种编码选自其它病原微生物或病毒抗原的异源基因。该启动子也可用于表达编码细胞因子如白细胞介素、肿瘤坏死因子或干扰素的异源DNA序列。已知数种细胞因子,如干扰素作为免疫调节剂而起重要作用。因此在apxIV启动子的控制下表达这样的遗传信息可能是优越的。因此,本发明的另一实施方案涉及带有控制apxIV基因表达启动子的核苷酸序列。
在自然状态下控制apxIV基因表达的可开关启动子现被发现位于SEQID NO:5中位置451和1132之间的DNA片段中。很明显该DNA片段中那些非启动子必需成分的部分不必要存在于该片段中。因此,保留该启动子活性的此DNA片段的较短部分同样适用于异源基因的表达。因此,该实施方案更为优选的形式涉及包括SEQ ID NO:5中位置451到1132DNA片段或其仍具有启动子活性子片段的核苷酸序列。
细菌启动子均具有两个共有区,所谓的-10和-35区。虽然这些共有区的侧翼序列可能在一定程度上影响启动子的效率,仅使用包括-35与ATG密码子之间的DNA片段的启动子区域部分可能是优越的。该DNA片段位于SEQ ID NO:5的位置617与位置641之间。因此,在本发明该实施方案更为优选的形式中涉及包括SEQ ID NO:5中位置617至641之间DNA片段的核苷酸序列。
本发明也涉及作为亚单位疫苗成分的ApxIV毒素。亚单位疫苗将最为可能包括这三种已知的Apx-毒素。这一点上面已经提到。然而,如上述,由于意外地发现ApsIV毒素存在于所有胸膜肺炎放线杆菌血清型中,故其是亚单位疫苗理想的添加成分:产生的抗ApxIV毒素的中和抗体提供了对无论什么血清型的每种及所有胸膜肺炎放线杆菌株所产生ApxIV毒素的保护。因此,本发明的另一个实施方案涉及用于保护动物免受胸膜肺炎放线杆菌细菌感染的亚单位疫苗,其中包括纯化的ApxIV毒素。ApxIV毒素可单独施用,或与任何或所有上述的毒素ApxI、-II和-III结合施用和/或,例如,与胸膜肺炎放线杆菌外膜蛋白(OMPs)结合施用。可通过将ApxIV毒素以足以诱导免疫反应的量与药物上可接受的载体混合而容易地制备该疫苗。通过在适当的表达载体中导入apxIV基因、表达该基因及分离毒素而制备ApxIV毒素是可能的。本领域中已知有多种通用表达系统,如细胞表达系统,杆状病毒表达系统及哺乳动物细胞表达系统。在实施例3中描述了如何通过大肠杆菌中表达该基因而获得ApxIV毒素。
本发明的另一实施方案涉及活减毒疫苗,其中包括上述用于保护动物免受胸膜肺炎放线杆菌感染的活减毒细菌。这种疫苗可通过将活减毒细菌与药物上可接受的载体混合而获得。这些疫苗包括至少免疫原性有效量的根据本发明活减毒产生菌。免疫原性有效量意思为接种时施用的活减毒菌的量足以在宿主内诱导对产生毒性形式RTX-毒素菌的有效免疫反应。待施用的有用剂量将随着年龄、体重及接种的动物,施用的方式和接种所要针对病原体的类型而改变。此疫苗包括足以导致免疫反应的任何剂量的细菌。例如,103与105个细菌之间的剂量范围是很合适的剂量。
药物上可接受的载体可以是简单的如水,但其也可以包括,例如,在其中培养细菌的培养液。其它合适的载体例如,生理盐浓度的溶液。用于本发明其它药物上可接受载体或稀释剂的实例包括稳定剂如SPGA、碳水化合物(如山梨醇、甘露醇、淀粉、蔗糖、葡萄糖、葡聚糖)、蛋白如清蛋白或酪蛋白、含有蛋白如牛血清或去脂牛奶的试剂及缓冲液(如磷酸盐缓冲液)。
任选地,具有佐剂活性的一种或多种化合物可加入到疫苗中。佐剂为非特异性的免疫系统刺激剂。它们增强宿主对入侵病原体的免疫反应。本领域已知佐剂的实例有弗氏完全和不完全佐剂,维生素E,非离子型嵌段聚合物,胞壁酰二肽,ISCOMs(免疫刺激复合物,参考如欧洲专利EP109942),皂角苷,矿物油,植物油和Carbopol(均聚物)。特别是适用于粘膜应用的佐剂有,例如,大肠杆菌热不稳定性毒素(LT)或霍乱毒素(CT)。
其它合适的佐剂有,例如,氢氧化铝,磷酸铝或氧化铝,油性乳剂(如Bayol F(R)或Marcol52(R),皂角苷或维生素E-加溶物。
因此,在优选形式中,根据本发明的疫苗包括佐剂。
为了施用到动物,根据本发明的疫苗可特别地以鼻内、皮内、皮下、通过烟雾剂或肌肉内施用。
有几种保存亚单位和活生物的方式。例如在冰箱内保存是众所周知的方法。在含有甘油的缓冲液中于-70℃保存也常使用。细菌也可保存于液氮中。冷冻干燥是另一种保存方式。冷冻干燥的细菌可被保存并维持存活多年。冷冻干燥的细菌的保存温度可位于零度以上而不损害其存活力。冷冻干燥同样适用于亚单位。
冷冻干燥可根据众所周知的标准冷冻干燥方法加以完成。任选有利的添加剂,如去脂牛奶、海藻糖、明胶或牛血清白蛋白可在冷冻过程中加入。
因此,在更为优选的实施方案中,根据本发明的疫苗是冷冻的形式。
在该实施方案更为优选的形式中,疫苗还额外包括一种或多种选自其它病原体微生物或病毒的抗原。这种疫苗可通过将选自其它病原菌或病毒的一种或多种抗原添加到根据本发明的活减毒菌及上述药物上可接受的载体中而获得。
当然,不仅添加一种或多种抗原,而且添加一种或多种整个病原体如,失活或活性形式病原体是可能的。
作为选择,可用上述已知的重组DNA技术将编码一种或多种选自其它病原微生物或病毒的抗原的遗传信息克隆到活减毒菌中而获得疫苗。无论从医学还是从身体角度看,这种疫苗当然较以每种病原体单独接种对接种的动物产生较小的协迫。
在甚至更为优选的形式中,这些抗原选自猪生殖呼吸综合症(PRRS)病毒、伪狂犬病毒、猪流感病毒、猪细小病毒、传染性胃肠炎病毒、轮状病毒、大肠杆菌、猪丹毒丝菌、多杀巴斯德氏菌、支气管炎博德特氏菌、副猪嗜血菌及猪链球菌。
本发明也涉及不能产生有功能ApxIV毒素的各种活减毒胸膜肺炎放线杆菌的制备方法。这些方法包括在编码apxIV蛋白的基因中导入突变。用诱变剂的经典突变技术和本领域众所周知的用于apxIV基因遗传信息插入、替代或缺失的重组DNA技术是可用的。
在更为优选的形式中,上述方法用于导入缺失。
包括将根据本发明的细菌与药物上可接受的载体混合的用于本发明活减毒疫苗制备的方法也是本发明的一部分。
用于亚单位疫苗制备的方法也在本发明的范围之内。该方法包括将纯化的ApxIV毒素与药物上可接受的载体混合。
在活疫苗接种领域中另一个普遍认识到的问题如下:在宿主动物血清中抗某种病原体抗体的存在表明该宿主已被此毒性或减毒形式的病原体感染。然而区分野外感染的动物与以活疫苗菌株接种的动物是不可能的。根据本发明的活体减毒胸膜肺炎放线杆菌按如下提供了该问题的解决方案:如在实施例3中所述,胸膜肺炎放线杆菌血清型1的apxIV基因已被分离并在异源宿主细胞中表达。将此表达产物进行PAAGE-凝胶电泳且然后用于Western-印迹。将印迹与获自以胸膜肺炎放线杆菌有意识感染猪的恢复期血清及获自野生菌株感染的血清孵育。发现apxIV基因在所有测试的胸膜肺炎放线杆菌野生菌株中均有体内表达。这表明以胸膜肺炎放线杆菌感染的猪将一直具有抗所有感染菌株血清型的感染它们的菌株的抗体。由于apxIV基因的缺失,根据本发明的活减毒菌不再产生ApxIV毒素。因此以本发明的活减毒胸膜肺炎放线杆菌菌株接种的动物在其血清中将不具有抗ApxIV毒素的抗体。
在比较测试,如ELISA测试中,该血清将因此与所有免疫原性的胸膜肺炎放线杆菌-蛋白如ApxI、II和/或III反应,但将不与ApxIV起反应。然而,以胸膜肺炎放线杆菌野生菌株感染猪的血清将与所有免疫原性的胸膜肺炎放线杆菌-蛋白,包括ApxIV起反应。因此,根据本发明的活减毒胸膜肺炎放线杆菌证明是很适宜的标记疫苗,即可与野生菌株区分的疫苗菌株。
用于区分疫苗菌株与野生菌株的诊断测试可以是简单的ELISA-测试,其中的纯化ApxIV毒素涂到ELISA-平板的孔壁上。然后与待测的猪血清孵育,接着与,如标记的抗猪抗体孵育可显示抗ApxIV毒素的抗体存在与否。
另一种诊断测试系统的实例是,如,将包括纯化ApxIV毒素的Western印迹与待测的猪血清孵育,接着检测特异性的抗-ApxIV抗体。
因此,用于区分以胸膜肺炎放线杆菌野生菌株感染猪的血清与以包括本发明活减毒疫苗胸膜肺炎放线杆菌菌株疫苗接种猪的血清(包括纯化ApxIV毒素)的诊断测试也在本发明的范围之内。
猪健康保护中的另一问题如下:即难以用快捷而清晰的方式测定猪是否以胸膜肺炎放线杆菌或猪放线杆菌感染,或是二者共同感染。目前还没有用于对猪放线杆菌特异性检测的诊断测试。这主要是由于这样的事实,即胸膜肺炎放线杆菌与猪放线杆菌共有许多相同的抗原。两种高度抗原性的Apx-毒素可作为实例;在如猪放线杆菌中,ApxI与ApxII具有高度保守的同源物(Van Ostaayen等.,待发表)。
编码ApxI、-II和-III毒素或同源物的已知RTX基因实际上发现于放线杆菌属的所有成员中,如胸膜肺炎放线杆菌、猪放线杆菌、罗氏放线杆菌及马驹放线杆菌。因此,本发明者最初认为,新的RTX-毒素ApxIV在所有放线杆菌属成员中是相同的。然而,测试猪病原性放线杆菌后发现,又一次与已知三种RTX-基因惊奇地形成鲜明对照,即该新的RTX-基因apxIV仅存在于猪病原体胸膜肺炎放线杆菌中。其没有出现于所有其它常见的猪病原性放线杆菌各种类中,且因此它也没有出现于猪放线杆菌中。见实施例6和7。因此,令人惊奇地注意到猪血清中抗ApxIV抗体的存在是猪被胸膜肺炎放线杆菌感染而不是被猪放线杆菌或任何其它猪病原体放线杆菌种类感染的快捷而又清晰的证据。
这样,本发明也提供了基于抗ApxIV抗体存在与否的诊断测试,且因此用于特异性区分胸膜肺炎放线杆菌感染与猪放线杆菌感染的区别测试。这种测试可以是,如,ELISA测试,其在分离的小孔中包括既存在于胸膜肺炎放线杆菌又存在于猪放线杆菌中的ApxI及-II毒素和纯化的ApxIV毒素。猪放线杆菌感染的动物血清将仅与包括ApxI和Apx-II的小孔起反应而胸膜肺炎放线杆菌感染的动物也将与包括纯化ApxIV毒素的小孔起反应。
实施例1:
胸膜肺炎放线杆菌血清型1apxIV基因的克隆与分析
标准的分子生物学方法(质粒DNA分离,限制性酶切、琼脂糖凝胶电泳、Southern印迹、连接、转化、电穿孔),如果没有另作说明,基本上按Sambrook等(分子克隆,实验手册,冷泉港、纽约,1989)或Ausubel等(当前分子生物学方法,John Wiley &Sons,纽约,1987)的描述进行。PCR基本上按Innis等(PCR方法,方法及应用指南,学术出版公司,圣地亚哥,1990)所述进行。染色体DNA分离根据Pitcher等(应用微生物学通迅8;151-156,1989)完成。所有胸膜肺炎放线杆菌参比菌株(血清型1:菌株4074;血清型2:菌株S1536:血清型3:S1421;血清型4M62;血清型5a:K17;血清型5b:L20;血清型6:femφ;血清型7:WF83;血清型8:405;血清型9:CVI13261;血清型10:13039;血清型11:56153及血清型12:8329)的来源由Frey和Nicolet描述(临床微生物杂志,28;232-236,1990)。胸膜肺炎放线杆菌血清型3菌株HV114为野生型分离子(即在Beck等,临床微生物学杂志.,32;2749-2754,1994中测试的血清型3菌株之一)。所用的其它放线杆菌菌株;罗氏放线杆菌:ATCC27072;马驹放线杆菌:ATCC19392;猪放线杆菌:ATCC15558。溶血巴斯德氏菌1型菌株ATCC14003被使用。
所用的大肠杆菌宿主菌株:XL1-blue(Stratagene,La Yolla,Ca;基因型:rec A1 end A1 gyrA96 thi-1 hsd R17 sup E44 rel A 1lac[F’proABlaclq ZDM 15 Tn10(Tetr)])及HMS174(DE3)(AMS生物技术公司,瑞士;基因型:F-rec A(rk12-mk12+)rifr IDE3)。根据获自T.J.,Anderson论文的初步序列数据(Guelph大学,1995),合成两条命名为APXIVA-1L(5’-TGGCACTGACGGTGATGA-3’)和APXIVA-1R(5’-GGCCATCGACTCAACCAT-3’)的引物。这些引物用于以胸膜肺炎放线杆菌血清型3菌株HV114和血清型1参照菌株4074的染色体DNA作为模板的PCR扩增中。用两种菌株扩增出442bp的片段。将获自血清型3染色体DNA的此片段根据制造商方法手册以洋地黄毒苷-11-dUTP(宝灵曼)标记(此片段命名为探针APXIVA,见图4)。随后将该标记探针用于与含有ClaI消化的菌株4074染色体DNA的Southern印迹杂交。该探针与大约8.0kb的片段杂交。血清型1菌株4074的apxIV基因通过将ClaI消化的染色体DNA连接到ClaI消化的pBluescript II SK-(Stratagene美国)中而加以分离。以连接的DNA转化大肠杆菌菌株XL1-blue并将转化体于含有100mg/ml氨苄青霉素的LB平板上进行筛选。
用APXIVA探针通过平板硝酸纤维素复制品的菌落杂交筛选带有apxIV的克隆。这样,分离到命名为pROK7的质粒并显示其带有约8kb的ClaI插入子。将ClaI插入子的头6736bp进行测序(SEQ ID1)并鉴定出编码具有约186KD预期大小的编码1657个氨基酸残基蛋白(SEQID2)的4971个核苷酸的开放阅读框。该基因命名为apxIV-var1(见图3)。
实施例2:
胸膜肺炎放线杆菌血清型3apxIV基因的克隆与分析
将标记的探针APXIVA(在实施例1中提到)用于与含有ClaI消化的HV114菌株染色体DNA的Southern印迹杂交。探针与约7.0kb的片段杂交。将从HV114分离的染色体DNA以ClaI消化,并与ClaI消化的pBluescript II SK-(Stratagene美国)连接。以连接的DNA转化大肠杆菌菌株XL1-blue并于具有100mg/ml氨苄青霉素的LB平板上筛选转化体。用APXIVA探针通过平板的硝酸纤维素复制品的菌落杂交筛选带有apxIV的克隆。因此,分离出一个名为pROK5的质粒并显示其带有约7kb的ClaI插入子。通过序列分析分析该插入子(SEQ ID 3)。鉴定出一个4146bp的开放阅读框,其编码具有约154KD预期大小的1382氨基酸残基的蛋白(SEQ ID 4)。该基因命名为apxIV-var3(见图3)。
实施例3:
ApxIV var3-多聚组氨酸融合蛋白在大肠杆菌中的表达
由质粒pROK5,制备一个缺失克隆,其中含有apxIV基因的3’末端,从Bam HI位点(SEQ ID NO:3中核苷酸NO.2747)到apxIV基因插入下游末端的ClaI位点。将该质粒命名为pROK1。用寡核苷酸APXIVAHIS1-L(5’-AGCCATATGGGCGATTTAAATTTCAG-3’)及APXIVAHIS1-R(5’-TATGGATCCTCCGTGCTTCTGAGC-3’)和质粒pROK1 DNA作为模板,扩增出2.1kb的DNA片段(见图4),其中含有分别位于5’和3’末端NdeI及BamHI限制性位点两侧的apxIV-var3(SEQID3)中3520到5643bp的区域。在表达载体pETHIS-1中克隆NdeI/BamHI消化的PCR片段后,以相同的酶消化,获得名为pJFFapxIV6/10 his-1的质粒。质粒pETHIS-1是pET14b(Novagen公司.,Madison,Wi)的衍生物,其中的多克隆位点已被扩展且已插入编码组氨酸十聚体(decamer)的区域。因而,pJFFapxIV6/10 his-1质粒含有T7启动子控制下的翻译融合体,其编码组氨酸六聚体、后接SEQ ID4中653到1360氨基酸残基,后面再接上组氨酸十聚体。将此质粒转化至具有pLysS的大肠杆菌菌株HMS174(DE3)中,其中含有IPTG可诱导的T7RNA聚合酶基因和用于增加稳定性的T7溶菌酶基因。将该菌株培养于含25mg/ml氯霉素及100mg/ml的氨苄青霉素的LB培养基至0.5的OD650,并以10mM浓度的异丙基-b-D-硫代吡喃半乳糖苷诱导。添加IPTG以后,细胞于37℃孵育2.5小时,离心收获细胞,并且分离包涵体形式的80kD预期大小的融合蛋白。将包涵体溶解于pH8.0的6M盐酸胍、300mM NaCl和50mMNaH2PO4溶液中且80kD融合蛋白通过用Ni2+螯合柱(Qiagen AG,Basel)的固定金属亲和层析(IMAC)(Schmitt等,分子生物学报告18;223-230,1993)进一步加以纯化。以pH5.0从柱中洗脱纯净蛋白。将收集的馏份于pH8.0的300mM NaCl和50mM NaH2PO4溶液中透析。以用1体积完全弗氏佐剂(Difco实验室,Detroit,MI)混合的500mg多聚组氨酸融合产物免疫兔子。3周后施以混合有不完全弗氏佐剂的相同量的增强剂量。增强免疫后四周,将兔子放血并获得包括抗-ApxIV毒素抗体称为血清522-409的超免疫血清。
实施例4:
apxIV基因在体外培养的胸膜肺炎放线杆菌中的表达
将血清型1的胸膜肺炎放线杆菌参比菌株培养于补充以10mg/ml b-NAD的Columbia肉汤中并按所述(Beck等,临床微生物杂志,32;2749-2754,1994)进行收获。在相邻于包括ApxIA、ApxIIA和ApxIVA-多聚组氨酸融合蛋白道的位置通过聚丙烯酰胺凝胶电泳(Laemmli,自然227:680-685,1970)分离浓缩的培养上清并进行Western印迹方法(Towbin等,美国自然科学院院报76:4350-4354,1979)。将Western印迹按Beek等所述(临床微生物学杂志,32;2749-2754,1994)与抗-ApxIA-和抗-ApxIIA单克隆抗体及抗-ApxIV血清522-409(见实施例3)起反应。分离的血清型1RTX毒素馏份清楚地含有ApxIA和ApxIIA。ApxIVA的存在没能得到证实(见图5)。
实施例5:
apxIV基因在胸膜肺炎放线杆菌感染期间的体内表达
将含有80kD多聚组氨酸-ApxIV-var3融合蛋白(见实施例3)的聚丙烯酰胺凝胶转移至硝酸纤维素膜上。将该膜分成细条带(strips)与抗血清型1的(100倍稀释的)恢复期野生血清或以血清型1的参比菌株(Frey和Nicolet,兽医微生物学,28;61-73,1991)实验性感染的猪血清起反应。用碱性磷酸酶标记的抗兔IgG的偶联物(Kirkegaard Perry公司,Graithersburg,Md)与NBT(4-氮蓝四唑氯化物)及BCIP(5-溴-4-氯-3-吲哚基-磷酸酯)显色观察反应(见图6)。血清型1野生型血清及实验性感染的猪血清与80kD的多聚组氨酸-ApxIV-var3蛋白反应。这表明ApxIV蛋白实际上表达,具有抗原性且在猪中胸膜肺炎放线杆菌感染过程中诱导抗-ApxIV毒素抗体。
实施例6:
用Southern印迹(证明)apxIV基因在所有胸膜肺炎放线杆菌血清型中的存在及其在非胸膜肺炎放线杆菌菌株中的不存在
为了研究apxIV基因在各种胸膜肺炎放线杆菌血清型及相关细菌中的存在,制备三种探针(见图4)。探针APXIVA在实施例1中描述过。探针APXIVA2在BamHI和NruI位点之间含有2015bp的DNA片段。通过用寡聚体APPIV1-L(5’-GGGACAGTGGCTCAATTAAG-3’)和(APPIV1-R(5’-AGCTGTAAACTCCACCAACG-3’)的PCR扩增制备758bp的探针APPIVA1。所有的探针根据制造商手册以洋地黄毒苷-11-dUTP(宝灵曼)标记并与Southern印迹杂交,印迹中含有所有胸膜肺炎放线杆菌参比菌株和HV114野生菌株、猪放线杆菌(ATCC15558)、罗氏放线杆菌(ATCC27072)及马驹放线杆菌(ATCC19392)的ClaI消化的染色体DNA。所有三个探针反应类似(见图7APXIVA2探针的结果)。所有的胸膜肺炎放线杆菌菌株反应,而没有观察到与猪放线杆菌、马驹放线杆菌及罗氏放线杆菌菌株的反应。
实施例7:
用PCR扩增(证实)apxIV基因在胸膜肺炎放线杆菌及相关菌株中的存在
用来自各种胸膜肺炎放线杆菌血清型、其它放线杆菌种类及溶血巴斯德氏菌的50ng染色体DNA作为模板,及引物APXIVA-1L(5’-TGGCACTGACGGTGATGA-3’)和APXIVA-IR(5’-GGCCATCGACTCAACCAT-3’进行PCR扩增。产物在琼脂糖凝胶上分析以后,在所有胸膜肺炎放线杆菌样品中观察到442bp预期大小的产物,但没有在其它放线杆菌种类中观察到(图8)。这表明除了实施例6中的结果外,PCR也可用于区分胸膜肺炎放线杆菌与其它放线杆菌种类。
实施例8:
ApxIV-var1多聚组氨酸融合蛋白的过量表达
以质粒pROK-7(见实施例1)作为模板且寡核苷酸APX4/II5-L(5’-CGCCATATGACAAAATTAACTATGCAAG)及APX4II6-R(5’-CGCGAATTCAGCGACACAAGAGATAT)作为PCR-引物开始,扩增PCR片段。然后将足够量的该片段以限制性酶NdeI和EcoRI消化并克隆入实施例3中所述的以相同酶消化的表达载体pETHIS-1中。根据得到的命名为pJFFApxIVA1His1的质粒,按实施例3中所述在大肠杆菌中过量表达206kD的1841个氨基酸残基的多聚组氨酸融合蛋白(PAGE中测定的MW)。如在SEQ ID NO:5中所述,该蛋白由横跨其中no.1132至6546核酸的编码区所编码。蛋白的氨基酸序列显示于SEQ ID NO:6中。在Western印迹中,显示此产物与特异性的抗-ApxIV血清522-409反应(实施例3中描述的抗血清)。
实施例9:
通过以ApxIV接种保护小鼠免受APP感染
两种均源自血清型1参比菌株4074基因组材料的在实施例8中所述206KD多聚组氨酸-ApxIV融合蛋白和相应的108KD多聚组氨酸-ApxIA-融合蛋白按实施例3中所述过量表达。将诱导大肠杆菌细胞的细胞沉淀物重悬于PBS缓冲液(1g细胞沉淀于6ml缓冲液中)并于冰上45秒钟超声粉碎2次用于细胞裂解。以22.000xg 4℃离心20分钟后,弃上清并将3M的尿素(pH6.3)溶液洗得到的沉淀。22.000xg离心20分钟后去除尿素,并将得到的沉淀溶于6M的盐酸胍(pH8.0)中。经PAGE凝胶的光密度测定后通过特定蛋白的浓度对蛋白样品进行标准化。样品以PBS稀释并以油性佐剂配制。
15只小鼠为一组共3组以ApxIV抗原(36.3微克)、ApxIA抗原(36.3微克)或仅以佐剂进行腹膜内免疫。以0.4ml体积施用疫苗。第一次接种24天后,将每组小鼠分成7只和8只小鼠的两组,均以一半量的抗原增强免疫。7只小鼠的组以0.2ml的体积在腹膜内进行增强免疫且8只小鼠的组以0.1ml每只于后肢进行肌肉内接种。增强免疫13天后,将小鼠1.5108cfu的毒性血清型1菌株腹膜内感染。
实施例10:
ApxIV的孔道形成能力:
表达ApxIV的新鲜诱导的大肠杆菌用作用于按Maier等,感染免疫,64;4415-4423(1996)所述在人工脂双层中测试孔道形成的蛋白来源。用于黑色脂双层实验的方法以前已有描述(Benz等;生物化学生物物理学报511:305-319(1978)。膜由1%的asolection溶液(Sigma的大豆凝集素型IV-S,St,Louis MO)于正癸烷中形成。形成10倍跨膜盐梯度后5-10分钟用Keithley 610C静电计测量零电流膜电势(Zero currentmembrane potential)(Benz等,生物化学生物物理杂志551:238-247(1979)。在0.5%胆固醇存在时ApxIV的存在导致高频率的孔道形成,平均单个通道电导率(G)为4nS。
这些结果表示ApxIV诱导进入人工双层的孔道且因此对真核细胞是有毒的且因此为胸膜肺炎放线杆菌的毒性因子。
附图说明:
图1:ApxIVA var1和ApxIVA var3(var代表血清型)的比较。图示发现于C-末端的不同特征。阴影框代表ApxIVA中的同向重复区域。黑体竖线表示富含甘氨酸非肽(nonapeptides)的位置,且DNA聚合酶家族B特征以黑三角形表示。氨基酸序列YSDSANSKK代表ApxIVA var3基因中的间隔序列。在ApxIVAvar3中被缺失的ApxIVAvar1序列片段也显示于图中。
图2:ApxIVA var1和ApxIVA var3的同向重复1(A)、同向重复2(B)及同向重复3(C)的氨基酸序列的比较。同向重复1,2和3的每个拷贝由字母标记以区分它们用于序列比较。变异的残基以黑体字母显示。
图3:pBLac7(T.J.Anderson学位论文.University ofGuelph,1995),pROK7和pROK5的部分限制性图谱。不同的开放阅读框(ORF’s)以箭头表示。pROK7中的lacZ断箭头表示该基因的部分测序。潜在的rho-非依赖性转录终止子被标出(W)。潜在的转录起点由三角形标出。限制性位点:A=Asp700;B=BamHI;C=ClaI;E=EcoRV;Ec=EcoRI;H=HindIII;N=NruI;Nd=NdeI,Nh=NheI;P=PstI;S=SpeI;Sm=SmI。
图4:各种寡核苷酸和探针在apxIVA var3基因图谱上的位置。
图5:ApxIV在体外培养的血清型1参比菌株4074中的表达。A板与抗-ApxIA单克隆抗体反应,板B与抗-ApxIIA单克隆抗体反应且板C与抗-ApxIVA血清522-409反应。1道含有ApxIA-多聚组氨酸融合蛋白,2道含有ApxIIA-多聚组氨酸融合蛋白,3道含有菌株4074浓缩培养物上清,4道含有ApxIVA多聚组氨酸融合蛋白。
图6:显示以参比菌株血清型1实验性感染的猪血清(1道)或以80KD多聚组氨酸融合蛋白血清型1野生感染猪血清(2-4道)反应性的免疫印迹。使用血清522-409作为阳性对照(+),用1000-倍稀释的多克隆兔抗ApxI和ApxII(Frey等,感染免疫,57;2050-2056,1989)血清作为阴性对照(-)。
图7:与探针APXIVA2杂交的ClaI消化的基因组DNA的Southern印迹。1-13泳道:胸膜肺炎放线杆菌参比菌株;1:血清型1;2:血清型2;3:血清型;4:血清型4;5:血清型5a;6:血清型5b;7:血清型6;8:血清型7;9:血清型8;10:血清型9;11:血清型10;12:血清型11;13:血清型12;14:HV114野生菌株;15:猪放线杆菌(ATCC15558);16:罗氏放线杆菌(ATCC27072);17:马驹放线杆菌(ATCC 19392)。分子大小标记(以千碱基对)显示于左边。
图8:用引物APXIVA-1L和APXIVA-1R的PCR扩增。泳道分配:1到13泳道分别含有胸膜肺炎放线杆菌参比菌株的1、2、3、4、5a、5b、6、7、8、9、10、11和12血清型;14泳道:菌株HV114;15泳道:猪放线杆菌ATCC 15558;16泳道:罗氏放线杆菌ATCC 27072;17泳道:马驹放线杆菌ATCC 19392;18泳道:李氏放线杆菌(A.lignieresii)ATCC 49236;19泳道:溶血巴斯德氏菌1型ATCC14003。分子大小标记(以千碱基对)显示于左边。
序列表(1)一般信息:
(i)申请人:
(A)名称:AKZO Noble N.V.
(B)街道:Velperweg 76
(C)城市:Arnhem
(E)国家:荷兰
(F)邮编:(ZIP):6824BM
(ii)发明题目:活体减毒胸膜肺炎放线杆菌
(iii)序列数目:4
(iv)计算机可读形式:
(A)介质类型:软盘
(B)计算机:IBM PC兼容机
(C)操作系统:PC-DOS/MS-DOS
(D)软件:专利发布#1.0,1.30版(EPO)(2)SEQ ID NO:1信息:
(i)序列特征:
(A)长度:6736个碱基对
(B)类型:核酸
(C)链型:双链
(D)拓扑学:线性
(ii)分子类型:DNA(基因组)
(iii)假设条件:无
(iv)反义:无
(vi)最初来源:
(A)有机体:胸膜肺炎放线杆菌
(B)菌株:4074(血清型1参比菌株)
(vii)直接来源
(B)克隆:pROK7
(ix)特征:
(A)名字/关键:CDS
(B)位置:1576…6549
(D)其它信息/密码子-起始-1576
/功能=“RTX毒素”
/产物:“ApxIV_var1”
/基因=“apxIV_var1”
/数目=1
(xi)序列描述:SEQ ID NO:1:ATCGATATGC CGCCGGGTAC GGGCGATATC CAACTTACTC TTTCGCAACA AATTCCGGTT 60ACCGGTGCGG TGGTGGTAAC CACTCCGCAA GATATTGCGT TATTAGATGC GGTGAAAGGT 120ATTTCAATGT TCCAAAAAGT GTCGGTACCG GTCTTAGGTA TCATTGAAAA TATGAGCGTA 180CATATCTGCC AAAATTGCGG TCACCACGAA GATATTTTCG GCACCGGCGG TGCGGAGAAA 240GTGGCGAAGA AATACGGTAC TAAAGTATTA GGACAAATGC CGTTGCATAT TCGCTTACGT 300CAAGATTTGG ATGCCGGCAC ACCGACCGTC GTTGCGGCAC CGGAACACGA AACCAGCCGA 360GCCTATATTG AATTAGCGGC AAAAGTCGCT TCGGAATTAT ACTGGCAAGG TTCGGTTATC 420CCGTCTGAAA TTATGATTCG TGAAGTAAAA TAAGTTTTAA TAACCACGAA AACACAAAGA 480ACACAAGCGG TAGAATTTGC AGAAAAATTT GCAAATCCTA CCGCTTTTTT ATTAGTACGA 540TTCGCTGTTG GACTGCTATT TGATTTGGTT TGTCAGGATA TTATGTTATT GTAATGAAAT 600GTTAGTGAAT TATTTTTATT AATTTGAAAG GAAACAAAAT GAAAATAAAA AAACGTTACA 660TTGCGCTGTT GGTCTTAGGT GTCGTTATCA GCTATGCCTG GTATCAAAAT TATCAATGGG 720AACAGCTGAT GTTAAGCGGT TATTGTGAAA AGGACGGAAG TTATTTTGAT GATAGGCATA 780CGAAGCAAGA ACTGATTGAT AGGGCAATTA ACTATATGCT GGAGCATCAA TCTAAAAAAA 840CATACGATGC TTATACTGAT GAACCTTTAG AAATAAAACC ATATTTAACA ATAGAGGAAT 900TTAAAAAACT CAATCCAAAT TGTTGTGAAA TTACCTCATG GCCAGCAGAT GCAGTTCCAC 960AAGATTGGGA TGTTCGTGTG GAAGGTAAGG CATATAGGTA TGTAATCGTA AAATATTTAA 1020GAACCTTAGC AAATAGAGAA CCTGAACGAT GGGAAACTAG TATTGTTTTT GATAATTGCG 1080GCAATCCTAA AAGAGCAAGC TACTTATATT ATTTAAAGAG AGAAATTTAT TATGACAAAA 1140TTAACTATGC AAGATGTGAC CAATTTATAT TTATATAAAA CGAAAACTCT ACCTAAAGAT 1200AGATTGGATG ATTCACTTAT TTCTGAAATA GGAAAAGGAG ATGATGATAT TGATAGAAAA 1260GAATTTATGG TGGGGCCGGG ACGTTTTGTG ACCGCTGATA ACTTTAGCGT TGTAAGAGAT 1320TTTTTTAATG CTGGGAAATC ACGCATTATT GCGCCGCAAG TCCCGCCTAT TCGTTCACAG 1380CAGGAAAAAA TCTTGGTCGG TTTAAAACCG GGCAAATATT CCAAAGCGCA GATATTGGAA 1440ATGCTGGGTT ATACGAAAGG CGGAGAAGTG GTAAATGGCA TGTTTGCCGG TGAAGTCCAG 1500ACATTAGGCT TTTATGACGA TGGCAAAGGG GATTTACTCG AACGCGCCTA TATCTGGAAT 1560ACCACAGGAT TTAAA ATG AGC GAC AAT GCC TTT TTT GTT ATA GAA GAA TCA 1611
Met Ser Asp Asn Ala Phe Phe Val Ile Glu Glu Ser
1 5 10GGC AAA CGC TAT ATT GAA AAC TTT GGT ATT GAA CCT CTT GGT AAG CAA 1659Gly Lys Arg Tyr Ile Glu Asn Phe Gly Ile Glu Pro Leu Gly Lys Gln
15 20 25GAA GAT TTT GAT TTT GTC GGC GGC TTT TGG TCT AAC TTA GTG AAT CGT 1707Glu Asp Phe Asp Phe Val Gly Gly Phe Trp Ser Asn Leu Val Asn Arg
30 35 40GGT TTG GAA AGT ATT ATC GAC CCA TCC GGT ATC GGT GGA ACG GTA AAC 1755Gly Leu Glu Ser Ile Ile Asp Pro Ser Gly Ile Gly Gly Thr Val Asn45 50 55 60CTT AAC TTT ACC GGC GAG GTG GAA ACC TAC ACG TTA GAC GAA ACA AGG 1803Leu Asn Phe Thr Gly Glu Val Glu Thr Tyr Thr Leu Asp Glu Thr Arg
65 70 75TTT AAA GCG GAA GCG GCG AAG AAA AGC CAT TGG AGT TTA GTG AAT GCG 1851Phe Lys Ala Glu Ala Ala Lys Lys Ser His Trp Ser Leu Val Asn Ala
80 85 90GCG AAA GTA TAC GGC GGT TTA GAC CAA ATT ATT AAA AAA CTA TGG GAC 1899Ala Lys Val Tyr Gly Gly Leu Asp Gln Ile Ile Lys Lys Leu Trp Asp
95 100 105AGT GGC TCA ATT AAG CAT TTA TAT CAA GAT AAA GAT ACG GGC AAA TTA 1947Ser Gly Ser Ile Lys His Leu Tyr Gln Asp Lys Asp Thr Gly Lys Leu
110 115 120AAA CCG ATT ATT TAC GGC ACG GCC GGC AAC GAC AGT AAG ATT GAA GGC 1995Lys Pro Ile Ile Tyr Gly Thr Ala Gly Asn Asp Ser Lys Ile Glu Gly125 130 135 140ACT AAA ATC ACC CGT AGG ATT GCG GGT AAA GAA GTT ACG CTT GAT ATT 2043Thr Lys Ile Thr Arg Arg Ile Ala Gly Lys Glu Val Thr Leu Asp Ile
145 150 155GCC AAT CAG AAA ATT GAA AAA GGC GTG TTA GAG AAA TTG GGG CTG TCT 2091Ala Asn Gln Lys Ile Glu Lys Gly Val Leu Glu Lys Leu Gly Leu Ser
160 165 170GTT AGT GGT TCG GAT ATC ATT AAA TTG TTG TTT GGA GCA TTG ACT CCA 2139Val Ser Gly Ser Asp Ile Ile Lys Leu Leu Phe Gly Ala Leu Thr Pro
175 180 185ACT TTA AAT AGA ATG TTG CTA TCA CAA CTT ATC CAG TCT TTT TCC GAT 2187Thr Leu Asn Arg Met Leu Leu Ser Gln Leu Ile Gln Ser Phe Ser Asp
190 195 200AGC TTG GCT AAA CTT GAT AAT CCC TTA GCC CCT TAC ACT AAA AAT GGC 2235Ser Leu Ala Lys Leu Asp Asn Pro Leu Ala Pro Tyr Thr Lys Asn Gly205 210 215 220GTG GTT TAT GTC ACC GGC AAA GGG AAT GAT GTG CTT AAA GGA ACT GAA 2283Val Val Tyr Val Thr Gly Lys Gly Asn Asp Val Leu Lys Gly Thr Glu
225 230 235CAT GAG GAT TTG TTT CTC GGT GGT GAG GGG AAT GAT ACT TAT TAT GCG 2331His Glu Asp Leu Phe Leu Gly Gly Glu Gly Asn Asp Thr Tyr Tyr Ala
240 245 250AGA GTA GGC GAT ACA ATT GAA GAC GCC GAC GGC AAA GGT AAA GTC TAT 2379Arg Val Gly Asp Thr Ile Glu Asp Ala Asp Gly Lys Gly Lys Val Tyr
255 260 265TTT GTG AGA GAA AAA GGG GTA CCT AAG GCG GAT CCT AAG CGG GTA GAG 2427Phe Val Arg Glu Lys Gly Val Pro Lys Ala Asp Pro Lys Arg Val Glu
270 275 280TTT AGC GAG TAC ATA ACG AAA GAA GAA ATA AAA GAG GTT GAA AAG GGG 2475Phe Ser Glu Tyr Ile Thr Lys Glu Glu Ile Lys Glu Val Glu Lys Gly285 290 295 300TTA TTA ACT TAC GCA GTT TTA GAA AAT TAT AAT TGG GAA GAG AAA ACG 2523Leu Leu Thr Tyr Ala Val Leu Glu Asn Tyr Asn Trp Glu Glu Lys Thr
305 310 315GCG ACT TTC GCT CAT GCG ACT ATG CTT AAT GAG CTT TTT ACT GAT TAT 2571Ala Thr Phe Ala His Ala Thr Met Leu Asn Glu Leu Phe Thr Asp Tyr
320 325 330ACT AAT TAT CGT TAT GAA GTT AAA GGA CTA AAA TTG CCC GCC GTT AAA 2619Thr Asn Tyr Arg Tyr Glu Val Lys Gly Leu Lys Leu Pro Ala Val Lys
335 340 345AAG TTA AAA AGT CCG TTG GTG GAG TTT ACA GCT GAT TTA TTA ACT GTT 2667Lys Leu Lys Ser Pro Leu Val Glu Phe Thr Ala Asp Leu Leu Thr Val
350 355 360ACG CCT ATT GAC GAA AAC GGA AAA GCA CTT AGC GAA AAA AGT ATT ACG 2715Thr Pro Ile Asp Glu Asn Gly Lys Ala Leu Ser Glu Lys Ser Ile Thr365 370 375 380GTT AAA AAT TTT AAA AAT GGT GAT TTA GGA ATA AGG TTG TTG GAT CCT 2763Val Lys Asn Phe Lys Asn Gly Asp Leu Gly Ile Arg Leu Leu Asp Pro
385 390 395AAT AGC TAT TAT TAT TTC CTT GAA GGC CAA GAT ACG GGT TTT TAT GGT 2811Asn Ser Tyr Tyr Tyr Phe Leu Glu Gly Gln Asp Thr Gly Phe Tyr Gly
400 405 410CCT GCT TTT TAT ATT GAA CGA AAA AAC GGT GGC GGC GCT AAA AAT AAC 2859Pro Ala Phe Tyr Ile Glu Arg Lys Asn Gly Gly Gly Ala Lys Asn Asn
415 420 425TCG TCG GGA GCA GGA AAT AGC AAA GAT TGG GGC GGG AAC GGG CAT GGA 2907Ser Ser Gly Ala Gly Asn Ser Lys Asp Trp Gly Gly Asn Gly His Gly
430 435 440AAT CAC CGA AAT AAT GCC TCC GAC CTG AAT AAA CCG GAC GGA AAT AAT 2955Asn His Arg Asn Asn Ala Ser Asp Leu Asn Lys Pro Asp Gly Asn Asn445 450 455 460GGG AAT AAC CAA AAT AAC GGA AGC AAT CAA GAT AAT CAT AGC GAT GTG 3003Gly Asn Asn Gln Asn Asn Gly Ser Asn Gln Asp Asn His Ser Asp Val
465 470 475AAT GCG CCA AAT AAC CCG GGA CGT AAC TAT GAT ATT TAC GAT CCT TTA 3051Asn Ala Pro Asn Asn Pro Gly Arg Asn Tyr Asp Ile Tyr Asp Pro Leu
480 485 490GCT TTA GAT TTA GAT GGA GAT GGG CTT GAA ACC GTG TCG ATG AAC GGG 3099Ala Leu Asp Leu Asp Gly Asp Gly Leu Glu Thr Val Ser Met Asn Gly
495 500 505CGA CAA GGC GCG TTA TTC GAT CAT GAA GGA AAA GGT ATT CGT ACC GCA 3147Arg Gln Gly Ala Leu Phe Asp His Glu Gly Lys Gly Ile Arg Thr Ala
510 515 520ACG GGC TGG CTC GCT GCG GAT GAC GGT TTT TTA GTG TTA GAT CGT AAC 3195Thr Gly Trp Leu Ala Ala Asp Asp Gly Phe Leu Val Leu Asp Arg Asn525 530 535 540CAA GAC GGC ATT ATT AAT GAT ATA AGC GAG TTA TTT AGT AAT AAA AAT 3243Gln Asp Gly Ile Ile Asn Asp Ile Ser Glu Leu Phe Ser Asn Lys Asn
545 550 555CAA CTT TCC GAC GGC AGT ATT TCT GCA CAC GGT TTT GCG ACA TTA GCC 3291Gln Leu Ser Asp Gly Ser Ile Ser Ala His Gly Phe Ala Thr Leu Ala
560 565 570GAT TTG GAT ACA AAC CAA GAT CAG CGT ATC GAC CAA AAT GAT AAG CTG 3339Asp Leu Asp Thr Asn Gln Asp Gln Arg Ile Asp Gln Asn Asp Lys Leu
575 580 585TTT TCT AAA CTC CAA ATT TGG CGG GAT TTA AAT CAA AAC GGT TTT AGT 3387Phe Ser Lys Leu Gln Ile Trp Arg Asp Leu Asn Gln Asn Gly Phe Ser
590 595 600GAA GCG AAT GAG CTG TTT AGC TTA GAA AGT TTG AAT ATT AAA TCT TTA 3435Glu Ala Asn Glu Leu Phe Ser Leu Glu Ser Leu Asn Ile Lys Ser Leu605 610 615 620CAT ACC GCC TAT GAA GAG CGT AAT GAT TTT CTA GCG GGC AAT AAT ATC 3483His Thr Ala Tyr Glu Glu Arg Asn Asp Phe Leu Ala Gly Asn Asn Ile
625 630 635CTT GCT CAG CTT GGG AAG TAT GAA AAA ACG GAC GGT ACT TTT GCA CAA 3531Leu Ala Gln Leu Gly Lys Tyr Glu Lys Thr Asp Gly Thr Phe Ala Gln
640 645 650ATG GGC GAT TTA AAT TTC AGT TTT AAC CCG TTT TAT AGC CGA TTT ACC 3579Met Gly Asp Leu Asn Phe Ser Phe Asn Pro Phe Tyr Ser Arg Phe Thr
655 660 665GAA GCG TTA AAT TTA ACC GAG CAA CAA CGT CGC ACA ATT AAT CTA ACC 3627Glu Ala Leu Asn Leu Thr Glu Gln Gln Arg Arg Thr Ile Asn Leu Thr
670 675 680GGC ACC GGT CGG GTT CGG GAT TTG CGT GAA GCC GCC GCA CTT TCT GAG 3675Gly Thr Gly Arg Val Arg Asp Leu Arg Glu Ala Ala Ala Leu Ser Glu685 690 695 700GAG TTG GCT GCT TTA TTA CAA CAG TAC ACT AAG GCC TCC GAT TTT CAG 3723Glu Leu Ala Ala Leu Leu Gln Gln Tyr Thr Lys Ala Ser Asp Phe Gln
705 710 715GCA CAA CGA GAA TTA TTG CCT GCC ATT TTA GAT AAA TGG GCG GCA ACG 3771Ala Gln Arg Glu Leu Leu Pro Ala Ile Leu Asp Lys Trp Ala Ala Thr
720 725 730GAT TTA CAG TAT CAA CAT TAT GAT AAA ACA TTA CTT AAA ACG GTA GAA 3819Asp Leu Gln Tyr Gln His Tyr Asp Lys Thr Leu Leu Lys Thr Val Glu
735 740 745AGT ACC GAT AGT AGT GCT TCT GTC GTT AGA GTC ACG CCT TCT CAA TTA 3867Ser Thr Asp Ser Ser Ala Ser Val Val Arg Val Thr Pro Ser Gln Leu
750 755 760AGT AGT ATA CGC AAT GCA AAG CAT GAT CCT ACC GTT ATG CAA AAC TTT 3915Ser Ser Ile Arg Asn Ala Lys His Asp Pro Thr Val Met Gln Asn Phe765 770 775 780GAA CAG AGT AAG GCA AAA ATT GCG ACT TTA AAT TCG CTC TAC GGG TTA 3963Glu Gln Ser Lys Ala Lys Ile Ala Thr Leu Asn Ser Leu Tyr Gly Leu
785 790 795AAT ATC GAT CAA CTT TAT TAC ACG ACG GAT AAA GAC ATT CGC TAT ATT 4011Asn Ile Asp Gln Leu Tyr Tyr Thr Thr Asp Lys Asp Ile Arg Tyr Ile
800 805 810ACT GAT AAA GTG AAT AAT ATG TAT CAA ACA ACC GTA GAA CTT GCC TAC 4059Thr Asp Lys Val Asn Asn Met Tyr Gln Thr Thr Val Glu Leu Ala Tyr
815 820 825CGT TCT TTA CTT TTA CAA ACG CGT TTG AAG AAA TAT GTT TAT AGC GTT 4107Arg Ser Leu Leu Leu Gln Thr Arg Leu Lys Lys Tyr Val Tyr Ser Val
830 835 840AAT GCG AAA CAA TTC GAA GGG AAA TGG GTA ACC GAT TAT TCT CGT ACT 4155Asn Ala Lys Gln Phe Glu Gly Lys Trp Val Thr Asp Tyr Ser Arg Thr845 850 855 860GAA GCC TTA TTT AAC TCT ACT TTT AAA CAA TCG CCT GAA AAT GCA TTA 4203Glu Ala Leu Phe Asn Ser Thr Phe Lys Gln Ser Pro Glu Asn Ala Leu
865 870 875TAT GAT TTA AGC GAA TAC CTT TCT TTC TTT AAC GAT CCT ACG GAA TGG 4251Tyr Asp Leu Ser Glu Tyr Leu Ser Phe Phe Asn Asp Pro Thr Glu Trp
880 885 890AAA GAA GGG CTA TTA CTG TTA AGC CGT TAT ATA GAT TAT GCT AAA GCA 4299Lys Glu Gly Leu Leu Leu Leu Ser Arg Tyr Ile Asp Tyr Ala Lys Ala
895 900 905CAA GGA TTT TAT GAA AAC TGG GCG GCT ACT TCT AAC TTA ACT ATT GCC 4347Gln Gly Phe Tyr Glu Asn Trp Ala Ala Thr Ser Asn Leu Thr Ile Ala
910 915 920CGT TTA AGA GAG GCT GGA GTA ATT TTT GCA GAA TCG ACG GAT TTA AAA 4395Arg Leu Arg Glu Ala Gly Val Ile Phe Ala Glu Ser Thr Asp Leu Lys925 930 935 940GGC GAT GAA AAA AAT AAT ATT TTG TTA GGT AGC CAA AAA GAT AAT AAC 4443Gly Asp Glu Lys Asn Asn Ile Leu Leu Gly Ser Gln Lys Asp Asn Asn
945 950 955TTA TCG GGT AGT GCA GGT GAT GAT CTA CTT ATC GGC GGA GAG GGT AAT 4491Leu Ser Gly Ser Ala Gly Asp Asp Leu Leu Ile Gly Gly Glu Gly Asn
960 965 970GAT ACG TTA AAA GGC AGC TAC GGT GCA GAC ACC TAT ATC TTT AGC AAA 4539Asp Thr Leu Lys Gly Ser Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys
975 980 985GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT GAT AAC CGC 4587Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg
990 995 1000GCA AGA GAT ATC GAC ACC TTA AAA TTT ACC GAT GTG AAT TAT GCG GAA 4635Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu1005 1010 1015 1020GTG AAG TTT CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC GGT TAT CAT 4683Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His
1025 1030 1035GAT ACG GAT TCG GTC ACG GTA AAA TCC TTC TAC AGC CAT GTA GAT TAT 4731Asp Thr Asp Ser Val Thr Val Lys Ser Phe Tyr Ser His Val Asp Tyr
1040 1045 1050CAA TTT GAC AAA TTG GAG TTT GCT GAC CGC AGT ATA ACT CGC GAT GAA 4779Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu
1055 1060 1065CTG ATT AAA GCA GGG CTT CAT CTA TAC GGC ACC GAT GGC AAT GAT GAT 4827Leu Ile Lys Ala Gly Leu His Leu Tyr Gly Thr Asp Gly Asn Asp Asp
1070 1075 1080ATA AAG GAT CAT GCG GAT TGG GAC AGC ATT TTG GAA GGC GGC AAA GGC 4875Ile Lys Asp His Ala Asp Trp Asp Ser Ile Leu Glu Gly Gly Lys Gly1085 1090 1095 1100AAC GAT ATT CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT ATC TTT AGC 4923Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser
1105 1110 1115AAA GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT GAT AAC 4971Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn
1120 1125 1130CGC GCA AGA GAT ATC GAC ACC TTA AAA TTT ACT GAT GTG AAT TAT GCG 5019Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala
1135 1140 1145GAA GTG AAA TTC CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC GGT TAT 5067Glu Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr
1150 1155 1160CAT GAT ACG GAT TCG GTC ACG ATA AAA TCC TTC TAC AAC CAT GTA GAT 5115His Asp Thr Asp Ser Val Thr Ile Lys Ser Phe Tyr Asn His Val Asp1165 1170 1175 1180TAT CAA TTT GAC AAA TTG GAA TTT GCT GAC CGC AGT ATA ACT CGT GAT 5163Tyr Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp
1185 1190 1195GAA CTA GGT AAA CAA GGT ATG GCA TTA TTT GGC ACT GAC GGT GAT GAT 5211Glu Leu Gly Lys Gln Gly Met Ala Leu Phe Gly Thr Asp Gly Asp Asp
1200 1205 1210AAT ATC AAC GAC TGG GGA CGT AAC TCG GTG ATT GAT GCC GGT GCG GGT 5259Asn Ile Asn Asp Trp Gly Arg Asn Ser Val Ile Asp Ala Gly Ala Gly
1215 1220 1225AAT GAT ACG GTT AAT GGC GGT AAT GGC GAT GAC ACC CTC ATC GGC GGC 5307Asn Asp Thr Val Asn Gly Gly Asn Gly Asp Asp Thr Leu Ile Gly Gly
1230 1235 1240AAA GGT AAT GAT ATT CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT ATC 5355Lys Gly Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile1245 1250 1255 1260TTT AGC AAA GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT 5403Phe Ser Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn
1265 1270 1275GAT AAC CGC GCA AGA GAT ATC GAC ACC TTA AAA TTT ACC GAT GTG AAT 5451Asp Asn Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn
1280 1285 1290TAT GCG GAA GTG AAA TTC CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC 5499Tyr Ala Glu Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe
1295 1300 1305GGT TAT CAT GAT ACG GAT TCG GTC ACG GTA AAA TCC TTC TAC AGC CAT 5547Gly Tyr His Asp Thr Asp Ser Val Thr Val Lys Ser Phe Tyr Ser His
1310 1315 1320GTA GAT TAT CAA TTT GAC AAA TTG GAG TTT GCT GAC CGC AGT ATA ACT 5595Val Asp Tyr Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr1325 1330 1335 1340CGC GAT GAA CTG ATT AAA GCA GGG CTT CAT CTA TAC GGC ACC GAT GGC 5643Arg Asp Glu Leu Ile Lys Ala Gly Leu His Leu Tyr Gly Thr Asp Gly
1345 1350 1355AAT GAT GAT ATA AAG CAT CAT GCG GAT TGG GAC AGC ATT TTG GAA GGC 5691Asn Asp Asp Ile Lys Asp His Ala Asp Trp Asp Ser Ile Leu Glu Gly
1360 1365 1370GGC AAA GGC AAC GAT ATT CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT 5739Gly Lys Gly Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr
1375 1380 1385ATC TTT AGC AAA GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT 5787Ile Phe Ser Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn
1390 1395 1400AAT GAT AAC CGA GCA AGA GAT ATC GAC ACC TTA AAA TTT ACT GAT GTG 5835Asn Asp Asn Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val1405 1410 1415 1420AAT TAT GCG GAA GTG AAA TTC CGA CGA GTA GAT AAT GAC TTA ATG TTA 5883Asn Tyr Ala Glu Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu
1425 1430 1435TTC GGT TAT CAT GAT ACG GAT TCG GTC ACG ATA AAA TCC TTC TAC AAC 5931Phe Gly Tyr His Asp Thr Asp Ser Val Thr Ile Lys Ser Phe Tyr Asn
1440 1445 1450CAT GTA GAT TAT CAA TTT GAC AAA TTG GAA TTT GCT GAC CGC AGT ATA 5979His Val Asp Tyr Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile
1455 1460 1465ACT CGT GAT GAA CTA GGT AAA CAA GGT ATG GCA TTA TTT GGC ACT GAC 6027Thr Arg Asp Glu Leu Gly Lys Gln Gly Met Ala Leu Phe Gly Thr Asp
1470 1475 1480GGT GAT GAT AAT ATC AAC GAC TGG GGA CGT AAC TCG GTG ATT GAT GCC 6075Gly Asp Asp Asn Ile Asn Asp Trp Gly Arg Asn Ser Val Ile Asp Ala1485 1490 1495 1500GGT GCG GGT AAT GAT ACG GTT AAT GGC GGT AAT GGC GAT GAC ACC CTC 6123Gly Ala Gly Asn Asp Thr Val Asn Gly Gly Asn Gly Asp Asp Thr Leu
1505 1510 1515ATC GGC GGC AAA GGT AAT GAT ATT CTA AGA GGT GGC TAC GGT GCG GAC 6171Ile Gly Gly Lys Gly Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp
1520 1525 1530ACC TAT ATC TTT AGC AAA GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT 6219Thr Tyr Ile Phe Ser Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp
1535 1540 1545ACC AAT AAT GAT AAC CGC GCA AGA GAT ATC GAC ACC TTA AAA TTT ACT 6267Thr Asn Asn Asp Asn Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr
1550 1555 1560GAT ATT AAT TTA TCC GAA CTT TGG TTT AGC CGA GAA AAT AAC GAT TTG 6315Asp Ile Asn Leu Ser Glu Leu Trp Phe Ser Arg Glu Asn Asn Asp Leu1565 1570 1575 1580ATT ATT AAA TCA TTA TTA AGT GAG GAT AAA GTC ACG GTT CAA AAT TGG 6363Ile Ile Lys Ser Leu Leu Ser Glu Asp Lye Val Thr Val Gln Asn Trp
1585 1590 1595TAT TCA CAC CAA GAT CAT AAA ATA GAA AAT ATT CGT TTA TCG AAT GAG 6411Tyr Ser His Gln Asp His Lys Ile Glu Asn Ile Arg Leu Ser Asn Glu
1600 1605 1610CAA ACG TTG GTG AGC ACT CAG GTG GAG AAG ATG GTT GAG TCG ATG GCC 6459Gln Thr Leu Val Ser Thr Gln Val Glu Lys Met Val Glu Ser Met Ala
1615 1620 1625GGC TTT GCT CAG AAG CAC GGA GGA GAG ATA TCT CTT GTG TCG CTT GAA 6507Gly Phe Ala Gln Lys His Gly Gly Glu Ile Ser Leu Val Ser Leu Glu
1630 1635 1640GAG GTA AAA CAA TAT ATC AAT AGC TTA ACA GCT GCT TTA TAA 6549Glu Val Lys Gln Tyr Ile Asn Ser Leu Thr Ala Ala Leu *1645 1650 1655CATACGAAAG AAATCGGCAC AGTTTTTTTG AACTGTGCCG ATTTGATTTT AGTGTAAGAA 6609TATAGCCTGA TTTTAAGAAA TTTACTCTTG GCTAATAACT ATTTCCCATT TTATAAGTTA 6669TTGACGGATG GTTTTATCAA ATATGAGATC AAATCTTATT TTAAATTCGC TTTCCATTAA 6729GCGATAT 6736(2)SEQ ID NO:2信息:
(i)序列特征:
(A)长度:1658个氨基酸
(B)类型:氨基酸
(D)拓扑学:线性
(ii)分子类型:蛋白
(xi)序列描述:SEQ ID NO:2:Met Ser Asp Asn Ala Phe Phe Val Ile Glu Glu Ser Gly Lys Arg Tyr1 5 10 15Ile Glu Asn Phe Gly Ile Glu Pro Leu Gly Lys Gln Glu Asp Phe Asp
20 25 30Phe Val Gly Gly Phe Trp Ser Asn Leu Val Asn Arg Gly Leu Glu Ser
35 40 45Ile Ile Asp Pro Ser Gly Ile Gly Gly Thr Val Asn Leu Asn Phe Thr
50 55 60Gly Glu Val Glu Thr Tyr Thr Leu Asp Glu Thr Arg Phe Lys Ala Glu65 70 75 80Ala Ala Lys Lys Ser His Trp Ser Leu Val Asn Ala Ala Lys Val Tyr
85 90 95Gly Gly Leu Asp Gln Ile Ile Lys Lys Leu Trp Asp Ser Gly Ser Ile
100 105 110Lys His Leu Tyr Gln Asp Lys Asp Thr Gly Lys Leu Lye Pro Ile Ile
115 120 125Tyr Gly Thr Ala Gly Asn Asp Ser Lys Ile Glu Gly Thr Lys Ile Thr
130 135 140Arg Arg Ile Ala Gly Lys Glu Val Thr Leu Asp Ile Ala Asn Gln Lys145 150 155 160Ile Glu Lys Gly Val Leu Glu Lys Leu Gly Leu Ser Val Ser Gly Ser
165 170 175Asp Ile Ile Lys Leu Leu Phe Gly Ala Leu Thr Pro Thr Leu Asn Arg
180 185 190Met Leu Leu Ser Gln Leu Ile Gln Ser Phe Ser Asp Ser Leu Ala Lys
195 200 205Leu Asp Asn Pro Leu Ala Pro Tyr Thr Lys Asn Gly Val Val Tyr Val
210 215 220Thr Gly Lys Gly Asn Asp Val Leu Lys Gly Thr Glu His Glu Asp Leu225 230 235 240Phe Leu Gly Gly Glu Gly Asn Asp Thr Tyr Tyr Ala Arg Val Gly Asp
245 250 255Thr Ile Glu Asp Ala Asp Gly Lys Gly Lys Val Tyr Phe Val Arg Glu
260 265 270Lys Gly Val Pro Lys Ala Asp Pro Lys Arg Val Glu Phe Ser Glu Tyr
275 280 285Ile Thr Lys Glu Glu Ile Lys Glu Val Glu Lys Gly Leu Leu Thr Tyr
290 295 300Ala Val Leu Glu Asn Tyr Asn Trp Glu Glu Lys Thr Ala Thr Phe Ala305 310 315 320His Ala Thr Met Leu Asn Glu Leu Phe Thr Asp Tyr Thr Asn Tyr Arg
325 330 335Tyr Glu Val Lys Gly Leu Lys Leu Pro Ala Val Lys Lys Leu Lys Ser
340 345 350Pro Leu Val Glu Phe Thr Ala Asp Leu Leu Thr Val Thr Pro Ile Asp
355 360 365Glu Asn Gly Lys Ala Leu Ser Glu Lys Ser Ile Thr Val Lys Asn Phe
370 375 380Lys Asn Gly Asp Leu Gly Ile Arg Leu Leu Asp Pro Asn Ser Tyr Tyr385 390 395 400Tyr Phe Leu Glu Gly Gln Asp Thr Gly Phe Tyr Gly Pro Ala Phe Tyr
405 410 415Ile Glu Arg Lys Asn Gly Gly Gly Ala Lys Asn Asn Ser Ser Gly Ala
420 425 430Gly Asn Ser Lys Asp Trp Gly Gly Asn Gly His Gly Asn His Arg Asn
435 440 445Asn Ala Ser Asp Leu Asn Lys Pro Asp Gly Asn Asn Gly Asn Asn Gln
450 455 460Asn Asn Gly Ser Asn Gln Asp Asn His Ser Asp Val Asn Ala Pro Asn465 470 475 480Asn Pro Gly Arg Asn Tyr Asp Ile Tyr Asp Pro Leu Ala Leu Asp Leu
485 490 495Asp Gly Asp Gly Leu Glu Thr Val Ser Met Asn Gly Arg Gln Gly Ala
500 505 510Leu Phe Asp His Glu Gly Lys Gly Ile Arg Thr Ala Thr Gly Trp Leu
515 520 525Ala Ala Asp Asp Gly Phe Leu Val Leu Asp Arg Asn Gln Asp Gly Ile
530 535 540Ile Asn Asp Ile Ser Glu Leu Phe Ser Asn Lys Asn Gln Leu Ser Asp545 550 555 560Gly Ser Ile Ser Ala His Gly Phe Ala Thr Leu Ala Asp Leu Asp Thr
565 570 575Asn Gln Asp Gln Arg Ile Asp Gln Asn Asp Lys Leu Phe Ser Lys Leu
580 585 590Gln Ile Trp Arg Asp Leu Asn Gln Asn Gly Phe Ser Glu Ala Asn Glu
595 600 605Leu Phe Ser Leu Glu Ser Leu Asn Ile Lys Ser Leu His Thr Ala Tyr
610 615 620Glu Glu Arg Asn Asp Phe Leu Ala Gly Asn Asn Ile Leu Ala Gln Leu625 630 635 640Gly Lys Tyr Glu Lys Thr Asp Gly Thr Phe Ala Gln Met Gly Asp Leu
645 650 655Asn Phe Ser Phe Asn Pro Phe Tyr Ser Arg Phe Thr Glu Ala Leu Asn
660 665 670Leu Thr Glu Gln Gln Arg Arg Thr Ile Asn Leu Thr Gly Thr Gly Arg
675 680 685Val Arg Asp Leu Arg Glu Ala Ala Ala Leu Ser Glu Glu Leu Ala Ala
690 695 700Leu Leu Gln Gln Tyr Thr Lys Ala Ser Asp Phe Gln Ala Gln Arg Glu705 710 715 720Leu Leu Pro Ala Ile Leu Asp Lys Trp Ala Ala Thr Asp Leu Gln Tyr
725 730 735Gln His Tyr Asp Lys Thr Leu Leu Lys Thr Val Glu Ser Thr Asp Ser
740 745 750Ser Ala Ser Val Val Arg Val Thr Pro Ser Gln Leu Ser Ser Ile Arg
755 760 765Asn Ala Lys His Asp Pro Thr Val Met Gln Asn Phe Glu Gln Ser Lys
770 775 780Ala Lys Ile Ala Thr Leu Asn Ser Leu Tyr Gly Leu Asn Ile Asp Gln785 790 795 800Leu Tyr Tyr Thr Thr Asp Lys Asp Ile Arg Tyr Ile Thr Asp Lys Val
805 810 815Asn Asn Met Tyr Gln Thr Thr Val Glu Leu Ala Tyr Arg Ser Leu Leu
820 825 830Leu Gln Thr Arg Leu Lys Lys Tyr Val Tyr Ser Val Asn Ala Lys Gln
835 840 845Phe Glu Gly Lys Trp Val Thr Asp TyT Ser Arg Thr Glu Ala Leu Phe
850 855 860Asn Ser Thr Phe Lys Gln Ser Pro Glu Asn Ala Leu Tyr Asp Leu Ser865 870 875 880Glu Tyr Leu Ser Phe Phe Asn Asp Pro Thr Glu Trp Lys Glu Gly Leu
885 890 895Leu Leu Leu Ser Arg Tyr Ile Asp Tyr Ala Lys Ala Gln Gly Phe Tyr
900 905 910Glu Asn Trp Ala Ala Thr Ser Asn Leu Thr Ile Ala Arg Leu Arg Glu
915 920 925Ala Gly Val Ile Phe Ala Glu Ser Thr Asp Leu Lys Gly Asp Glu Lys
930 935 940Asn Asn Ile Leu Leu Gly Ser Gln Lys Asp Asn Asn Leu Ser Gly Ser945 950 955 960Ala Gly Asp Asp Leu Leu Ile Gly Gly Glu Gly Asn Asp Thr Leu Lys
965 970 975Gly Ser Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly His Gly Gln
980 985 990Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg Ala Arg Asp Ile
995 1000 1005Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu Val Lys Phe Arg
1010 1015 1020Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp Thr Asp Ser1025 1030 1035 1040Val Thr Val Lys Ser Phe Tyr Ser His Val Asp Tyr Gln Phe Asp Lys
1045 1050 1055Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu Ile Lys Ala
1060 1065 1070Gly Leu His Leu Tyr Gly Thr Asp Gly Asn Asp Asp Ile Lys Asp His
1075 1080 1085Ala Asp Trp Asp Ser Ile Leu Glu Gly Gly Lys Gly Asn Asp Ile Leu
1090 1095 1100Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly His Gly1105 1110 1115 1120Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg Ala Arg Asp
1125 1130 1135Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu Val Lys Phe
1140 1145 1150Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp Thr Asp
1155 1160 1165Ser Val Thr Ile Lys Ser Phe Tyr Asn His Val Asp Tyr Gln Phe Asp
1170 1175 1180Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu Gly Lys1185 1190 1195 1200Gln Gly Met Ala Leu Phe Gly Thr Asp Gly Asp Asp Asn Ile Asn Asp
1205 1210 1215Trp Gly Arg Asn Ser Val Ile Asp Ala Gly Ala Gly Asn Asp Thr Val
1220 1225 1230Asn Gly Gly Asn Gly Asp Asp Thr Leu Ile Gly Gly Lys Gly Asn Asp
1235 1240 1245Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly
1250 1255 1260His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg Ala1265 1270 1275 1280Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu Val
1285 1290 1295Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp
1300 1305 1310Thr Asp Ser Val Thr Val Lys Ser Phe Tyr Ser His Val Asp Tyr Gln
1315 1320 1325Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu
1330 1335 1340Ile Lys Ala Gly Leu His Leu Tyr Gly Thr Asp Gly Asn Asp Asp Ile1345 1350 1355 1360Lys Asp His Ala Asp Trp Asp Ser Ile Leu Glu Gly Gly Lys Gly Asn
1365 1370 1375Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys
1380 1385 1390Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg
1395 1400 1405Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu
1410 1415 1420Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His1425 1430 1435 1440Asp Thr Asp Ser Val Thr Ile Lys Ser Phe Tyr Asn His Val Asp Tyr
1445 1450 1455Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu
1460 1465 1470Leu Gly Lys Gln Gly Met Ala Leu Phe Gly Thr Asp Gly Asp Asp Asn
1475 1480 1485Ile Asn Asp Trp Gly Arg Asn Ser Val Ile Asp Ala Gly Ala Gly Asn
1490 1495 1500Asp Thr Val Asn Gly Gly Asn Gly Asp Asp Thr Leu Ile Gly Gly Lys1505 1510 1515 1520Gly Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe
1525 1530 1535Ser Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp
1540 1545 1550Asn Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Ile Asn Leu
1555 1560 1565Ser Glu Leu Trp Phe Ser Arg Glu Asn Asn Asp Leu Ile Ile Lys Ser
1570 1575 1580Leu Leu Ser Glu Asp Lys Val Thr Val Gln Asn Trp Tyr Ser His Gln1585 1590 1595 1600Asp His Lys Ile Glu Asn Ile Arg Leu Ser Asn Glu Gln Thr Leu Val
1605 1610 1615Ser Thr Gln Val Glu Lys Met Val Glu Ser Met Ala Gly Phe Ala Gln
1620 1625 1630Lys His Gly Gly Glu Ile Ser Leu Val Ser Leu Glu Glu Val Lys Gln
1635 1640 1645Tyr Ile Asn Ser Leu Thr Ala Ala Leu *
1650 1655(2)SEQ ID NO:3信息:
(i)序列特征:
(A)长度:7004个碱基对
(B)类型:核酸
(C)链型:双链
(D)拓扑学:线性
(ii)分子类型:DNA(基因组)
(iii)假设:无
(iv)反义:无
(vi)最初来源:
(A)有机体:胸膜肺炎放线杆菌
(B)菌株:HV114(血清型3野生菌株)
(vii)直接来源:
(B)克隆:pROK5
(ix)特征:
(A)名字/关键:CDS
(B)位置:1566…5714
(D)其它信息:/密码子-起始=1566
/功能=“RTX-毒素”
/产物=“ApxIV_var3”
/基因=“apxIV_var3”
/数目=1(xi)序列描述:SEQ ID NO:3:ATCGATATGC CGCCGGGTAC GGGCGATATC CAACTTACTC TTTCGCAACA AATTCCGGTT 60ACCGGTGCGG TAGTGGTAAC TACTCCGCAA GATATTGCGT TATTAGATGC GGTGAAAGGT 120ATTTCAATGT TCCAAAAAGT GTCGGTACCG GTCTTAGGTA TCATTGAAAA TATGAGCGTG 180CATATCTGCC AAAATTGCGG TCACCACGAA GATATTTTCG GCACCGGCGG TGCGGAGAAA 240GTGGCGAAGA AATACGGTAC TAAAGTATTA GGACAAATGC CGTTGCATAT TCGCTTACGT 300CAAGATTTGG ATGCCGGCAC ACCGACCGTC GTTGCGGCAC CGGAACACGA CACCAGCAGA 360GCCTATATTG AATTAGCGGC AAAAGTCGCT TCGGAATTAT ACTGGCAAGG TTCGGTTATC 420CCGTCTGAAA TTATGATTCG TGAAGTAAAA TAAGCCTACA TAACCACGGA ATACCAGATA 480ACACAGAAGG AAAACAAGCG GTAGAATTTG CAGAAAAAGT TGCAAATTCT ACCGCTTTTT 540TATTAGTACG ATTCGCTGTT GGACTGCCAT TTGATTTGGT TTGTCAGGAT ATTATGTTAT 600TGTAATGAAA TGTTAGTGAA TTATTTTTAT TAATTTGAAA GGAGACAAAA TGAAAATAAA 660AAAACGTTAC ATTGCGCTGC TAGCTTTAGG CAGTGTTATT GGCTATGCCT GGTATCAAAA 720TTATCAATGG GAACAGTTGA TGTTAAGTGG CTATTGTGAA AAGGACGGAA GCTATTGTGA 780TGATAGGCAT ACGAAGCAGG AACTGATTGA TAGGGCAATT AACTATGTGC TGGAAAATCA 840AATTCAACAG ACATATGAAG GTGATGACCT TGTGGATATA AAACAATATT CAACAATAGA 900GGAATTTAAA AAACTAAATC CGAATTGTTG TAAGGTAGAT TCTTGGCCGG ATGATGCTGT 960TCGTGAGGAT GCTGATTTAC AGCGAGAGGG CAAAGCGTAT AAATACGTAA AAGTCAAATA 1020TTTAAGAACC TATTTAGCGA ATAGAGAACC TGAACAATGG GAAAATTACA TAGTATTTGA 1080TAATTGCAGT GGAATTAAAG AAAGACACCA ACTGTATTAA AAATAGATTA GATGGAGACA 1140ACACGATGAC AAAACTAACT ATCCAAGATG TGACTAATTT ATATTTATAT AAGCAAAGAA 1200CTTTACCTAC GGATAGGTTA GATGATTCGC TTATTAGCAA AACAGGAAAA GGGGAAAATA 1260TTGATAAAAA GGAATTTATG GCGGGGCCGG GACGTTTTGT GACGGCCGAT AATTTTAGTG 1320TTGTAAAAGA CTTTTTTACT GCAAAGGATT CATTAATAAA CCTAAGCTTG CAGACTCGTA 1380TATTAGCGAA TTTAAAGCCG GGCAAATATT CCAAAGCGCA GATATTAGAA ATGTTGGGCT 1440ATACGAAAAA TGGAGAAAAG GTAGATGGCA TGTTTACCGG TGAAGTCCAG ACATTAGGCT 1500TTTATGACGA TGGCAAAGGG GATTTACTCG AACGCGCCTA TATCTGAAAT ACCACAGGAT 1560TTAAA ATG AGC GAC AAT GCC TTT TTT GTT ATA GAA GAA TCA GGC AAA 1607
Met Ser Asp Asn Ala Phe Phe Val Ile Glu Glu Ser Gly Lys
1660 1665 1670CGC TAT ATT GAA AAC TTT GGT ATT GAA CCT CTT GGT AAG CAA GAA GAT 1655Arg Tyr Ile Glu Asn Phe Gly Ile Glu Pro Leu Gly Lys Gln Glu Asp
1675 1680 1685TTT GAT TTT GTC GGC GGC TTT TGG TCT AAC TTA GTG AAT CGT GGT TTG 1703Phe Asp Phe Val Gly Gly Phe Trp Ser Asn Leu Val Asn Arg Gly Leu
1690 1695 1700GAA AGT ATT ATC GAC CCA TCC GGT ATC GGT GGA ACG GTA AAC CTT AAC 1751Glu Ser Ile Ile Asp Pro Ser Gly Ile Gly Gly Thr Val Asn Leu Asn1705 1710 1715 1720TTT ACC GGC GAG GTG GAA ACC TAC ACG TTA GAC GAA ACA AGG TTT AAA 1799Phe Thr Gly Glu Val Glu Thr Tyr Thr Leu Asp Glu Thr Arg Phe Lys
1725 1730 1735GCG GAA GCG GCG AAG AAA AGC CAT TGG AGT TTA GTG AAT GCG GCG AAA 1847Ala Glu Ala Ala Lys Lys Ser His Trp Ser Leu Val Asn Ala Ala Lys
1740 1745 1750GTA TAC GGC GGT TTA GAC CAA ATT ATT AAA AAA CTA TGG GAC AGT GGC 1895Val Tyr Gly Gly Leu Asp Gln Ile Ile Lys Lys Leu Trp Asp Ser Gly
1755 1760 1765TCA ATT AAG CAT TTA TAT CAA GAT AAA GAT ACG GGC AAA TTA AAA CCG 1943Ser Ile Lys His Leu Tyr Gln Asp Lys Asp Thr Gly Lys Leu Lys Pro
1770 1775 1780ATT ATT TAC GGC ACG GCC GGC AAC GAC AGT AAG ATT GAA GGC ACT AAA 1991Ile Ile Tyr Gly Thr Ala Gly Asn Asp Ser Lys Ile Glu Gly Thr Lys1785 1790 1795 1800ATC ACC CGT AGG ATT GCG GGT AAA GAA GTT ACG CTT GAT ATT GCC AAT 2039Ile Thr Arg Arg Ile Ala Gly Lys Glu Val Thr Leu Asp Ile Ala Asn
1805 1810 1815CAG AAA ATT GAA AAA GGC GTG TTA GAG AAA TTG GGG CTG TCT GTT AGT 2087Gln Lys Ile Glu Lys Gly Val Leu Glu Lys Leu Gly Leu Ser Val Ser
1820 1825 1830GGT TCG GAT ATC ATT AAA TTG TTG TTT GGA GCA TTG ACT CCA ACT TTA 2135Gly Ser Asp Ile Ile Lys Leu Leu Phe Gly Ala Leu Thr Pro Thr Leu
1835 1840 1845AAT AGA ATG TTG CTA TCA CAA CTT ATC CAG TCT TTT TCC GAT AGC TTG 2183Asn Arg Met Leu Leu Ser Gln Leu Ile Gln Ser Phe Ser Asp Ser Leu
1850 1855 1860GCT AAA CTT GAT AAT CCC TTA GCC CCT TAC ACT AAA AAT GGC GTG GTT 2231Ala Lys Leu Asp Asn Pro Leu Ala Pro Tyr Thr Lys Asn Gly Val Val1865 1870 1875 1880TAT GTC ACC GGC AAA GGG AAT GAT GTG CTT AAA GGA ACT GAA CAT GAG 2279Tyr Val Thr Gly Lys Gly Asn Asp Val Leu Lys Gly Thr Glu His Glu
1885 1890 1895GAT TTG TTT CTC GGT GGT GAG GGG AAT GAT ACT TAT TAT GCG AGA GTA 2327Asp Leu Phe Leu Gly Gly Glu Gly Asn Asp Thr Tyr Tyr Ala Arg Val
1900 1905 1910GGC GAT ACA ATT GAA GAC GCC GAC GGC AAA GGT AAA GTC TAT TTT GTG 2375Gly Asp Thr Ile Glu Asp Ala Asp Gly Lys Gly Lys Val Tyr Phe Val
1915 1920 1925AGA GAA AAA GGG GTA CCT AAG GCG GAT CCT AAG CGG GTA GAG TTT AGC 2423Arg Glu Lys Gly Val Pro Lys Ala Asp Pro Lys Arg Val Glu Phe Ser
1930 1935 1940GAG TAC ATA ACG AAA GAA GAA ATA AAA GAG GTT GAA AAG GGG TTA TTA 2471Glu Tyr Ile Thr Lys Glu Glu Ile Lys Glu Val Glu Lys Gly Leu Leu1945 1950 1955 1960ACT TAC GCA GTT TTA GAA AAT TAT AAT TGG GAA GAG AAA ACG GCG ACT 2519Thr Tyr Ala Val Leu Glu Asn Tyr Asn Trp Glu Glu Lys Thr Ala Thr
1965 1970 1975TTC GCT CAT GCG ACT ATG CTT AAT GAG CTT TTT ACT GAT TAT ACT AAT 2567Phe Ala His Ala Thr Met Leu Asn Glu Leu Phe Thr Asp Tyr Thr Asn
1980 1985 1990TAT CGT TAT GAA GTT AAA GGA CTA AAA TTG CCC GCC GTT AAA AAG TTA 2615Tyr Arg Tyr Glu Val Lys Gly Leu Lys Leu Pro Ala Val Lys Lys Leu
1995 2000 2005AAA AGT CCG TTG GTG GAG TTT ACA GCT GAT TTA TTA ACT GTT ACG CCT 2663Lys Ser Pro Leu Val Glu Phe Thr Ala Asp Leu Leu Thr Val Thr Pro
2010 2015 2020ATT GAC GAA AAC GGA AAA GCA CTT AGC GAA AAA AGT ATT ACG GTT AAA 2711Ile Asp Glu Asn Gly Lys Ala Leu Ser Glu Lys Ser Ile Thr Val Lys2025 2030 2035 2040AAT TTT AAA AAT GGT GAT TTA GGA ATA AGG TTG TTG GAT CCT AAT AGC 2759Asn Phe Lys Asn Gly Asp Leu Gly Ile Arg Leu Leu Asp Pro Asn Ser
2045 2050 2055TAT TAT TAT TTC CTT GAA GGC CAA GAT ACG GGT TTT TAT GGT CCT GCT 2807Tyr Tyr Tyr Phe Leu Glu Gly Gln Asp Thr Gly Phe Tyr Gly Pro Ala
2060 2065 2070TTT TAT ATT GAA CGA AAA AAC GGT GGA GGC TCT AAA AAT AAC TCG TCG 2855Phe Tyr Ile Glu Arg Lys Asn Gly Gly Gly Ser Lys Asn Asn Ser Ser
2075 2080 2085GGA GCA GGA AAT AGC AAA GAT TGG GGC GGG AAC GGG CAT GGA AAT CAC 2903Gly Ala Gly Asn Ser Lys Asp Trp Gly Gly Asn Gly His Gly Asn His
2090 2095 2100CGA AAT AAT GCC TCC GAC CTG AAT AAA CCG GAC GGA AAT AAT GGG AAT 2951Arg Asn Asn Ala Ser Asp Leu Asn Lys Pro Asp Gly Asn Asn Gly Asn2105 2110 2115 2120AAC CAA AAT AAC GGA AGC AAT CAA GAT AAT CAT AGC GAT GTG AAT GCG 2999Asn Gln Asn Asn Gly Ser Asn Gln Asp Asn His Ser Asp Val Asn Ala
2125 2130 2135CCA AAT AAC CCG GGA CGT AAC TAT GAT ATT TAC GAT CCT TTA GCT TTA 3047Pro Asn Asn Pro Gly Arg Asn Tyr Asp Ile Tyr Asp Pro Leu Ala Leu
2140 2145 2150GAT TTA GAT GGA GAT GGG CTT GAA ACC GTG TCG ATG AAC GGG CGA CAA 3095Asp Leu Asp Gly Asp Gly Leu Glu Thr Val Ser Met Asn Gly Arg Gln
2155 2160 2165GGC GCG TTA TTC GAT CAT GAA GGA AAA GGT ATT CGT ACC GCA ACG GGC 3143Gly Ala Leu Phe Asp His Glu Gly Lys Gly Ile Arg Thr Ala Thr Gly
2170 2175 2180TGG CTC GCT GCG GAT GAC GGT TTT TTA GTG TTA GAT CGT AAC CAA GAC 3191Trp Leu Ala Ala Asp Asp Gly Phe Leu Val Leu Asp Arg Asn Gln Asp2185 2190 2195 2200GGC ATT ATT AAT GAT ATA AGC GAG TTA TTT AGT AAT AAA AAT CAA CTT 3239Gly Ile Ile Asn Asp Ile Ser Glu Leu Phe Ser Asn Lys Asn Gln Leu
2205 2210 2215TCC GAC GGG AGT ATT TCT GCA CAC GGT TTT GCG ACA TTA GCC GAT TTG 3287Ser Asp Gly Ser Ile Ser Ala His Gly Phe Ala Thr Leu Ala Asp Leu
2220 2225 2230GAT ACA AAC CAA GAT CAG CGT ATC GAC CAA AAT GAT AAG CTG TTT TCT 3335Asp Thr Asn Gln Asp Gln Arg Ile Asp Gln Asn Asp Lys Leu Phe Ser
2235 2240 2245AAA CTC CAA ATT TGG CGG GAT TTA AAT CAA AAC GGT TTT AGT GAA GCG 3383Lys Leu Gln Ile Trp Arg Asp Leu Asn Gln Asn Gly Phe Ser Glu Ala
2250 2255 2260AAT GAG CTG TTT AGC TTA GAA AGT TTG AAT ATT AAA TCT TTA CAT ACC 3431Asn Glu Leu Phe Ser Leu Glu Ser Leu Asn Ile Lys Ser Leu His Thr2265 2270 2275 2280GCC TAT GAA GAG CGT AAT GAT TTT CTA GCG GGC AAT AAT ATC CTT GCT 3479Ala Tyr Glu Glu Arg Asn Asp Phe Leu Ala Gly Asn Asn Ile Leu Ala
2285 2290 2295CAG CTT GGG AAG TAT GAA AAA ACG GAC GGT ACT TTT GGA CAA ATG GGC 3527Gln Leu Gly Lys Tyr Glu Lys Thr Asp Gly Thr Phe Gly Gln Met Gly
2300 2305 2310GAT TTA AAT TTC AGT TTT AAC CCG TTT TAT AGC CGA TTT ACC GAA GCG 3575Asp Leu Asn Phe Ser Phe Asn Pro Phe Tyr Ser Arg Phe Thr Glu Ala
2315 2320 2325TTA AAT TTA ACC GAG CAA CAA CGT CGC ACA ATT AAT CTA ACC GGC ACC 3623Leu Asn Leu Thr Glu Gln Gln Arg Arg Thr Ile Asn Leu Thr Gly Thr
2330 2335 2340GGT CGG GTT CGG GAT TTG CGT GAA GCC GCC GCA CTT TCT GAG GAG TTG 3671Gly Arg Val Arg Asp Leu Arg Glu Ala Ala Ala Leu Ser Glu Glu Leu2345 2350 2355 2360GCT GCT TTA TTA CAA CAG TAC ACT AAG GGC TCC GAT TTT CAG GCA CAA 3719Ala Ala Leu Leu Gln Gln Tyr Thr Lys Gly Ser Asp Phe Gln Ala Gln
2365 2370 2375CGA GAA TTA TTG CCT GCC ATT TTA GAT AAA TGG GCG GCA ACG GAT TTA 3767Arg Glu Leu Leu Pro Ala Ile Leu Asp Lys Trp Ala Ala Thr Asp Leu
2380 2385 2390CAG TAT CAA CAT TAT GAT AAA ACA TTA CTT AAA ACG GTA GAA AGT ACC 3815Gln Tyr Gln His Tyr Asp Lys Thr Leu Leu Lys Thr Val Glu Ser Thr
2395 2400 2405GAT AGT AGT GCT TCT GTC GTT AGA GTC ACG CCT TCT CAA TTA AGT AGT 3863Asp Ser Ser Ala Ser Val Val Arg Val Thr Pro Ser Gln Leu Ser Ser
2410 2415 2420ATA CGC AAT GTA AAG CAT GAT CCT ACC GTT ATG CAA AAC TGT GAA CAA 3911Ile Arg Asn Val Lys His Asp Pro Thr Val Met Gln Asn Cys Glu Gln2425 2430 2435 2440AGT AAG GCA AAA ATT GCG ACT TTA AAT TCG CTC TAC GGG TTA AAT ATT 3959Ser Lys Ala Lys Ile Ala Thr Leu Asn Ser Leu Tyr Gly Leu Asn Ile
2445 2450 2455GAT CAA CTT TAT TAT ACG ACG GAT AAA GAC ATT CGT TAT ATT ACT GAC 4007Asp Gln Leu Tyr Tyr Thr Thr Asp Lys Asp Ile Arg Tyr Ile Thr Asp
2460 2465 2470AAA GTG AAT AAT ATG TAT CAA ACA ACC GGA GAA CTC GGC TAT CGT TCT 4055Lys Val Asn Asn Met Tyr Gln Thr Thr Gly Glu Leu Gly Tyr Arg Ser
2475 2480 2485TTA CTT TTA CAA ACG CGT GTG AAG AAA TAT GTT TAT AGC GTT AAT GCG 4103Leu Leu Leu Gln Thr Arg Val Lys Lys Tyr Val Tyr Ser Val Asn Ala
2490 2495 2500AAA CAA TTC GAA GGG AAA TGG GTA GCC GAT TAT TCT CGT ACT GAA GCC 4151Lys Gln Phe Glu Gly Lys Trp Val Ala Asp Tyr Ser Arg Thr Glu Ala2505 2510 2515 2520TTA TTT AAC TCT ACT TAT AAA CAA TCG CCC GAA AAT GTA TTA TAT GAT 4199Leu Phe Asn Ser Thr Tyr Lys Gln Ser Pro Glu Asn Val Leu Tyr Asp
2525 2530 2535TTA CGC GAA TAC CTT TCT TTC TAT AAC GAC CCT ACG GAA TGG AAA GAA 4247Leu Arg Glu Tyr Leu Ser Phe Tyr Asn Asp Pro Thr Glu Trp Lys Glu
2540 2545 2550GGG CTA TTA CTG TTA AGC CGT TAT ATA GAT TAT GCT AAA GCA CAA GGA 4295Gly Leu Leu Leu Leu Ser Arg Tyr Ile Asp Tyr Ala Lys Ala Gln Gly
2555 2560 2565TTT TAT GAA AAC TGG GCG GCT ACT TCT AAC TTA ACT ATT GCC CGT TTA 4343Phe Tyr Glu Asn Trp Ala Ala Thr Ser Asn Leu Thr Ile Ala Arg Leu
2570 2575 2580AGA GAG GCT GGA GTA ATT TGT GCA GAA TCG ACG GAT TTA AAA GGC GAT 4391Arg Glu Ala Gly Val Ile Cys Ala Glu Ser Thr Asp Leu Lys Gly Asp2585 2590 2595 2600GAA AAA AAT AAT ATT GTG TTA GGT AGC CAA AAA GAT AAT AAC TTA TCG 4439Glu Lys Asn Asn Ile Val Leu Gly Ser Gln Lys Asp Asn Asn Leu Ser
2605 2610 2615GGT AGT GCA GGT GAT GAT CTA CTT ATC GGC GGA GAG GGT AAT GAT ACG 4487Gly Ser Ala Gly Asp Asp Leu Leu Ile Gly Gly Glu Gly Asn Asp Thr
2620 2625 2630TTA AAA GGC AGC TAC GGT GCA GAC ACC TAT ATC TTT AGC AAA GGG CAT 4535Leu Lys Gly Ser Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly His
2635 2640 2645GGA CAA GAT GTA ATT TAT GAA TAT TCC GAC AGT GCA AAC TCT AAA AAA 4583Gly Gln Asp Val Ile Tyr Glu Tyr Ser Asp Ser Ala Asn Ser Lys Lys
2650 2655 2660GAT ATT GAT ACC TTA AAA TTT ACC GAT GTG AAT TAT GCG GAA GTG AAG 4631Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu Val Lys2665 2670 2675 2680TTT CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC GGT TAT CAT GAT ACG 4679Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp Thr
2685 2690 2695GAT TCG GTC ACG GTA AAA TCC TTC TAC AGC CAT GTA GAT TAT CAA TTT 4727Asp Ser Val Thr Val Lys Ser Phe Tyr Ser His Val Asp Tyr Gln Phe
2700 2705 2710GAC AAA TTG GAG TTT GCT GAC CGC AGT ATA ACT CGC GAT GAA CTG ATT 4775Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu Ile
2715 2720 2725AAA GCA GGG CTT CAT CTA TAC GGC ACC GAT GGC AAT GAT GAT ATA AAG 4823Lys Ala Gly Leu His Leu Tyr Gly Thr Asp Gly Asn Asp Asp Ile Lys
2730 2735 2740GAT CAT GCG GAT TGG GAC AGC ATT GTG GAA GGC GGC AAA GGC AAC GAT 4871Asp His Ala Asp Trp Asp Ser Ile Val Glu Gly Gly Lys Gly Asn Asp2745 2750 2755 2760ATT CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT ATC TTT AGC AAA GGA 4919Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly
2765 2770 2775CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT GAT AAC CGA GCA 4967His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg Ala
2780 2785 2790AGA GAT ATC GAC ACC TTA ACA TTT ACT GAT GTG AAT TAT GCG GAA GTG 5015Arg Asp Ile Asp Thr Leu Thr Phe Thr Asp Val Asn Tyr Ala Glu Val
2795 2800 2805AAA TTC CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC GGT TAT CAT GAT 5063Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp
2810 2815 2820ACG GAT TCG GTC ACG ATA AAA TCC TTC TAC AAC CAT GTA GAT TAT CAA 5111Thr Asp Ser Val Thr Ile Lys Ser Phe Tyr Asn His Val Asp Tyr Gln2825 2830 2835 2840TGT GAC AAA TTG GAC TTT GCT GAC CGC AGT ATA ACT CGT GAT GAA CTA 5159Cys Asp Lys Leu Asp Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu
2845 2850 2855GGT AAA CAA GGT ATG GCA TTA TTT GGC ACT GAC GGC GAT GAT AAT ATC 5207Gly Lys Gln Gly Met Ala Leu Phe Gly Thr Asp Gly Asp Asp Asn Ile
2860 2865 2870AAC GAC TGG GGA CGT AAC TCG GTG ATT GAT GCC GGT GCG GGT AAT GAT 5255Asn Asp Trp Gly Arg Asn Ser Val Ile Asp Ala Gly Ala Gly Asn Asp
2875 2880 2885ACG GTT AAT GGC GGT AAT GGC GAT GAC ACC CTC ATC GGC GGC AAA GGT 5303Thr Val Asn Gly Gly Asn Gly Asp Asp Thr Leu Ile Gly Gly Lys Gly
2890 2895 2900AAT GAT ATT CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT ATC TTT AGC 5351Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser2905 2910 2915 2920AAA GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT GAT AAC 5399Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn
2925 2930 2935CGC GCA AGA GAT ATC GAC ACC TTA AAA TTT ACT GAT ATT AAT TTA TCC 5447Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Ile Asn Leu Ser
2940 2945 2950GAA CTT TGG TTT AGC CGA GAA AAT AAC GAT TTG ATT ATT AAA TCA TTA 5495Glu Leu Trp Phe Ser Arg Glu Asn Asn Asp Leu Ile Ile Lys Ser Leu
2955 2960 2965TTA AGT GAG GAT AAA GTC ACG GTT CAA AAT TGG TAT TCA CAC CAA GAT 5543Leu Ser Glu Asp Lys Val Thr Val Gln Asn Trp Tyr Ser His Gln Asp
2970 2975 2980CAT AAA ATA GAA AAT ATT CGT TTA TCG AAT GAG CAA ATG TTG GTG AGC 5591His Lys Ile Glu Asn Ile Arg Leu Ser Asn Glu Gln Met Leu Val Ser2985 2990 2995 3000ACT CAG GTG GAG AAG ATG GTT GAG TCG ATG GCC GGC TTT GCT CAG AAG 5639Thr Gln Val Glu Lys Met Val Glu Ser Met Ala Gly Phe Ala Gln Lys
3005 3010 3015CAC GGA GGA GAG ATA TCT CTT CTG TCG CCT GAA GAG GTA AAA CAA TAT 5687His Gly Gly Glu Ile Ser Leu Leu Ser Pro Glu Glu Val Lys Gln Tyr
3020 3025 3030ATC AAT AGC TTA ACA GCT GCT TTA TAA CATACGAAAG AAATCGGCAC 5734Ile Asn Ser Leu Thr Ala Ala Leu *
3035 3040AGTTTTTGTG AACTGTGCCG ATTTGATTTT AGTGTAAGAA TATAGCCTGA TTTTAAGAAA 5794TTTACTCTTG GCTAATAACT ATTTCCCATT TTATAAGTTA TTGACGGATG GTTTTATCAA 5854ATATGAGATC AAATCTTATT TTAAATTCGC TTTCCATTAA GCGATATTGA TCTTTTAAGT 5914TTGGGGCCGC ATGAGTTTGG AACCGATACC ACTCATTGTG GGAATCAATA CACAATACGC 5974TGTAATCGGA CTCTTGCAGT TCATAATAAT GCTTTCTCTC CGTTAATTCT TCTTGCGTAT 6034ATGGCGAGAG ATTAAAGCTG AATGGCTGGT TCGCACTAAC AAACAGGTTC TCCGATTTCA 6094GATATTCACA ACCGTAATGG CTACCGGTTT CCTGCGGTTT TACATAATTG GTATGATTTT 6154GTTTAGCTGT TATACGGTAG ATGCCTAATT GTGGTAAATT GCGTGTGTCA ATATAGCTTT 6214CTTGTTCTCC GTAACCGAAA TACTCAATGG CGTTTTCTGT TTTAGCTAAG AAGAAACGTA 6274AGCCGAAGCG GGGTAAATAC GGTAATTCGA TCGGGCGAAT AGCGTTAATT TCAACCGAAA 6334GTTGTCCGTC ATTGAAGATA CGATAACGAA TATCCAGTGT TAAAATGCGA CCGCGAGAAA 6394TTGACACAAT TGCAGATTTT ACTGAAAATT CGACCGCTTG TTCGCTTTGC TGCCACTGAA 6454TTTCATACGC TCTGGTATAG GCTTTATCGT AGCCGGCATT TTGGCACGCC TCACGAATGA 6514GGCGATCATT GTCGGTTGGC GCACGCCAAA TATTAAAATC TAACGATTGT TGGATAATCG 6574CTTTACCGGC TTTTTCAATA CGGGTGAAAA TCCCTTTCTG TTTATCTAAT TGATAACTAA 6634ATTGACCGTT GTGTACGTTA ATGTGGAAGC GATCTTCTTG TACTTCAAAT GCACTGTTCT 6694CAATTGTGAA TTGTGGTAAT ACTAATTTAT TTTCGCTAAA TAAATTGAGC TGCTCGAAGC 6754CAAGTGAATG TGCTTCGTCT AATAATTCGA CCGCGGTATT TAAGCGATAA TTTAAATTCA 6814GTAGCCATAA ATGCCCGTTA TTTTTTGGTA ACTCAATCGG TAATACTACG CTGCCGTGCG 6874GTTGGCAAGA AACGGATAAA TTCCCACCGC TTGTCACCAC GCCGTTTTCG ACAAATTCGT 6934AATCAATCGT TAAATAATCG GCAAGATCAG TGAAATCCAA GTAGTTGTGG ATCACAATTT 6994GGTTATCGAT 7004(2)SEQ ID NO:4:信息:
(i)序列特征:
(A)长度:1383个氨基酸
(B)类型:氨基酸
(D)拓扑学:线性
(ii)分子类型:蛋白
(xi)序列描述:SEQ ID NO:4:Met Ser Asp Asn Ala Phe Phe Val Ile Glu Glu Ser Gly Lys Arg Tyr1 5 10 15Ile Glu Asn Phe Gly Ile Glu Pro Leu Gly Lys Gln Glu Asp Phe Asp
20 25 30Phe Val Gly Gly Phe Trp Ser Asn Leu Val Asn Arg Gly Leu Glu Ser
35 40 45Ile Ile Asp Pro Ser Gly Ile Gly Gly Thr Val Asn Leu Asn Phe Thr
50 55 60Gly Glu Val Glu Thr Tyr Thr Leu Asp Glu Thr Arg Phe Lys Ala Glu65 70 75 80Ala Ala Lys Lys Ser His Trp Ser Leu Val Asn Ala Ala Lys Val Tyr
85 90 95Gly Gly Leu Asp Gln Ile Ile Lys Lys Leu Trp Asp Ser Gly Ser Ile
100 105 110Lys His Leu Tyr Gln Asp Lys Asp Thr Gly Lys Leu Lys Pro Ile Ile
115 120 125Tyr Gly Thr Ala Gly Asn Asp Ser Lys Ile Glu Gly Thr Lys Ile Thr
130 135 140Arg Arg Ile Ala Gly Lys Glu Val Thr Leu Asp Ile Ala Asn Gln Lys145 150 155 160Ile Glu Lys Gly Val Leu Glu Lys Leu Gly Leu Ser Val Ser Gly Ser
165 170 175Asp Ile Ile Lys Leu Leu Phe Gly Ala Leu Thr Pro Thr Leu Asn Arg
180 185 190Met Leu Leu Ser Gln Leu Ile Gln Ser Phe Ser Asp Ser Leu Ala Lys
195 200 205Leu Asp Asn Pro Leu Ala Pro Tyr Thr Lys Asn Gly Val Val Tyr Val
210 215 220Thr Gly Lys Gly Asn Asp Val Leu Lys Gly Thr Glu His Glu Asp Leu225 230 235 240Phe Leu Gly Gly Glu Gly Asn Asp Thr Tyr Tyr Ala Arg Val Gly Asp
245 250 255Thr Ile Glu Asp Ala Asp Gly Lys Gly Lys Val Tyr Phe Val Arg Glu
260 265 270Lys Gly Val Pro Lys Ala Asp Pro Lys Arg Val Glu Phe Ser Glu Tyr
275 280 285Ile Thr Lys Glu Glu Ile Lys Glu Val Glu Lys Gly Leu Leu Thr Tyr
290 295 300Ala Val Leu Glu Asn Tyr Asn Trp Glu Glu Lys Thr Ala Thr Phe Ala305 310 315 320His Ala Thr Met Leu Asn Glu Leu Phe Thr Asp Tyr Thr Asn Tyr Arg
325 330 335Tyr Glu Val Lys Gly Leu Lys Leu Pro Ala Val Lys Lys Leu Lys Ser
340 345 350Pro Leu Val Glu Phe Thr Ala Asp Leu Leu Thr Val Thr Pro Ile Asp
355 360 365Glu Asn Gly Lys Ala Leu Ser Glu Lys Ser Ile Thr Val Lys Asn Phe
370 375 380Lys Asn Gly Asp Leu Gly Ile Arg Leu Leu Asp Pro Asn Ser Tyr Tyr385 390 395 400Tyr Phe Leu Glu Gly Gln Asp Thr Gly Phe Tyr Gly Pro Ala Phe Tyr
405 410 415Ile Glu Arg Lys Asn Gly Gly Gly Ser Lys Asn Asn Ser Ser Gly Ala
420 425 430Gly Asn Ser Lys Asp Trp Gly Gly Asn Gly His Gly Asn His Arg Asn
435 440 445Asn Ala Ser Asp Leu Asn Lys Pro Asp Gly Asn Asn Gly Asn Asn Gln
450 455 460Asn Asn Gly Ser Asn Gln Asp Asn His Ser Asp Val Asn Ala Pro Asn465 470 475 480Asn Pro Gly Arg Asn Tyr Asp Ile Tyr Asp Pro Leu Ala Leu Asp Leu
485 490 495Asp Gly Asp Gly Leu Glu Thr Val Ser Met Asn Gly Arg Gln Gly Ala
500 505 510Leu Phe Asp His Glu Gly Lys Gly Ile Arg Thr Ala Thr Gly Trp Leu
515 520 525Ala Ala Asp Asp Gly Phe Leu Val Leu Asp Arg Asn Gln Asp Gly Ile
530 535 540Ile Asn Asp Ile Ser Glu Leu Phe Ser Asn Lys Asn Gln Leu Ser Asp545 550 555 560Gly Ser Ile Ser Ala His Gly Phe Ala Thr Leu Ala Asp Leu Asp Thr
565 570 575Asn Gln Asp Gln Arg Ile Asp Gln Asn Asp Lys Leu Phe Ser Lys Leu
580 585 590Gln Ile Trp Arg Asp Leu Asn Gln Asn Gly Phe Ser Glu Ala Asn Glu
595 600 605Leu Phe Ser Leu Glu Ser Leu Asn Ile Lys Ser Leu His Thr Ala Tyr
610 615 620Glu Glu Arg Asn Asp Phe Leu Ala Gly Asn Asn Ile Leu Ala Gln Leu625 630 635 640Gly Lys Tyr Glu Lys Thr Asp Gly Thr Phe Gly Gln Met Gly Asp Leu
645 650 655Asn Phe Ser Phe Asn Pro Phe Tyr Ser Arg Phe Thr Glu Ala Leu Asn
660 665 670Leu Thr Glu Gln Gln Arg Arg Thr Ile Asn Leu Thr Gly Thr Gly Arg
675 680 685Val Arg Asp Leu Arg Glu Ala Ala Ala Leu Ser Glu Glu Leu Ala Ala
690 695 700Leu Leu Gln Gln Tyr Thr Lys Gly Ser Asp Phe Gln Ala Gln Arg Glu705 710 715 720Leu Leu Pro Ala Ile Leu Asp Lys Trp Ala Ala Thr Asp Leu Gln Tyr
725 730 735Gln His Tyr Asp Lys Thr Leu Leu Lys Thr Val Glu Ser Thr Asp Ser
740 745 750Ser Ala Ser Val Val Arg Val Thr Pro Ser Gln Leu Ser Ser Ile Arg
755 760 765Asn Val Lys His Asp Pro Thr Val Met Gln Asn Cys Glu Gln Ser Lys
770 775 780Ala Lys Ile Ala Thr Leu Asn Ser Leu Tyr Gly Leu Asn Ile Asp Gln785 790 795 800Leu Tyr Tyr Thr Thr Asp Lys Asp Ile Arg Tyr Ile Thr Asp Lys Val
805 810 815Asn Asn Met Tyr Gln Thr Thr Gly Glu Leu Gly Tyr Arg Ser Leu Leu
820 825 830Leu Gln Thr Arg Val Lys Lys Tyr Val Tyr Ser Val Asn Ala Lys Gln
835 840 845Phe Glu Gly Lys Trp Val Ala Asp Tyr Ser Arg Thr Glu Ala Leu Phe
850 855 860Asn Ser Thr Tyr Lys Gln Ser Pro Glu Asn Val Leu Tyr Asp Leu Arg865 870 875 880Glu Tyr Leu Ser Phe Tyr Asn Asp Pro Thr Glu Trp Lys Glu Gly Leu
885 890 895Leu Leu Leu Ser Arg Tyr Ile Asp Tyr Ala Lys Ala Gln Gly Phe Tyr
900 905 910Glu Asn Trp Ala Ala Thr Ser Asn Leu Thr Ile Ala Arg Leu Arg Glu
915 920 925Ala Gly Val Ile Cys Ala Glu Ser Thr Asp Leu Lys Gly Asp Glu Lys
930 935 940Asn Asn Ile Val Leu Gly Ser Gln Lys Asp Asn Asn Leu Ser Gly Ser945 950 955 960Ala Gly Asp Asp Leu Leu Ile Gly Gly Glu Gly Asn Asp Thr Leu Lys
965 970 975Gly Ser Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly His Gly Gln
980 985 990Asp Val Ile Tyr Glu Tyr Ser Asp Ser Ala Asn Ser Lys Lys Asp Ile
995 1000 1005Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu Val Lys Phe Arg
1010 1015 1020Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp Thr Asp Ser1025 1030 1035 1040Val Thr Val Lys Ser Phe Tyr Ser His Val Asp Tyr Gln Phe Asp Lys
1045 1050 1055Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu Ile Lys Ala
1060 1065 1070Gly Leu His Leu Tyr Gly Thr Asp Gly Asn Asp Asp Ile Lys Asp His
1075 1080 1085Ala Asp Trp Asp Ser Ile Val Glu Gly Gly Lys Gly Asn Asp Ile Leu
1090 1095 1100Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly His Gly1105 1110 1115 1120Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg Ala Arg Asp
1125 1130 1135Ile Asp Thr Leu Thr Phe Thr Asp Val Asn Tyr Ala Glu Val Lys Phe
1140 1145 1150Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp Thr Asp
1155 1160 1165Ser Val Thr Ile Lys Ser Phe Tyr Asn His Val Asp Tyr Gln Cys Asp
1170 1175 1180Lys Leu Asp Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu Gly Lys1185 1190 1195 1200Gln Gly Met Ala Leu Phe Gly Thr Asp Gly Asp Asp Asn Ile Asn Asp
1205 1210 1215Trp Gly Arg Asn Ser Val Ile Asp Ala Gly Ala Gly Asn Asp Thr Val
1220 1225 1230Asn Gly Gly Asn Gly Asp Asp Thr Leu Ile Gly Gly Lys Gly Asn Asp
1235 1240 1245Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly
1250 1255 1260His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg Ala1265 1270 1275 1280Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Ile Asn Leu Ser Glu Leu
1285 1290 1295Trp Phe Ser Arg Glu Asn Asn Asp Leu Ile Ile Lys Ser Leu Leu Ser
1300 1305 1310Glu Asp Lys Val Thr Val Gln Asn Trp Tyr Ser His Gln Asp His Lys
1315 1320 1325Ile Glu Asn Ile Arg Leu Ser Asn Glu Gln Met Leu Val Ser Thr Gln
1330 1335 1340Val Glu Lys Met Val Glu Ser Met Ala Gly Phe Ala Gln Lys His Gly1345 1350 1355 1360Gly Glu Ile Ser Leu Leu Ser Pro Glu Glu Val Lys Gln Tyr Ile Asn
1365 1370 1375Ser Leu Thr Ala Ala Leu *
1380(2)SEQ ID NO: 5信息:
(i)序列特征:
(A)长度:6736个碱基对
(B)类型:核酸
(C)链型:双链
(D)拓扑学:线性
(ii)分子类型:DNA(基因组)
(iii)假设:无
(iv)反义:无
(vi)最初来源:
(A)有机体:胸膜肺炎放线杆菌
(B)菌株:4074(血清型1参比菌株)
(vii)直接来源:
(B)克隆:pROK7
(ix)特征:
(A)名字/关键:CDS
(B)位置:1132…6549
(C)鉴定方法:实验
(D)其它信息:/密码子-起始=1132
/功能=“RTX毒素”
/产物=“ApxIV”
/证据=实验
/基因=“ApxIV_v1”
(ix)特征:
(A)名字/关键:CDS
(B)位置:639…1178
(D)其它信息:/密码子起始=639
/功能=“未知”
/产物=“ORF1”
/基因=“orf1”(ix)特征:
(A)名字/关键:CDS
(B)位置:1…453
(D)其它信息:/部分
/产物=“Met-G”
/基因=“mrp”
/标准_名=“mrp”
/标记=mrp(ix)特征:
(A)名字/关键:-10_信号
(B)位置:617…623
(D)其它信息:/标准_名字=“-10”
/标记=-10_S(ix)特征:
(A)名字/关键:-35信号
(B)位置:594..599
(D)其它信息:/标准_名字=“-35_S”
/标记:=-35_S(ix)特征:
(A)名字/关键:启动子
(B)位置:454…1131
(D)其它信息:/功能=“启动子”
/标准_名称=“启动子ApxIV”
/标记=启动子(ix)序列描述:SEQ ID NO:5:ATC GAT ATG CCG CCG GGT ACG GGC GAT ATC CAA CTT ACT CTT TCG CAA 48Ile Asp Met Pro Pro Gly Thr Gly Asp Ile Gln Leu Thr Leu Ser Gln1 5 10 15CAA ATT CCG GTT ACC GGT GCG GTG GTG GTA ACC ACT CCG CAA GAT ATT 96Gln Ile Pro Val Thr Gly Ala Val Val Val Thr Thr Pro Gln Asp Ile
20 25 30GCG TTA TTA GAT GCG GTG AAA GGT ATT TCA ATG TTC CAA AAA GTG TCG 144Ala Leu Leu Asp Ala Val Lys Gly Ile Ser Met Phe Gln Lys Val Ser
35 40 45GTA CCG GTC TTA GGT ATC ATT GAA AAT ATG AGC GTA CAT ATC TGC CAA 192Val Pro Val Leu Gly Ile Ile Glu Asn Met Ser Val His Ile Cys Gln
50 55 60AAT TGC GGT CAC CAC GAA GAT ATT TTC GGC ACC GGC GGT GCG GAG AAA 240Asn Cys Gly His His Glu Asp Ile Phe Gly Thr Gly Gly Ala Glu Lys65 70 75 80GTG GCG AAG AAA TAC GGT ACT AAA GTA TTA GGA CAA ATG CCG TTG CAT 288Val Ala Lys Lys Tyr Gly Thr Lys Val Leu Gly Gln Met Pro Leu His
85 90 95ATT CGC TTA CGT CAA GAT TTG GAT GCC GGC ACA CCG ACC GTC GTT GCG 336Ile Arg Leu Arg Gln Asp Leu Asp Ala Gly Thr Pro Thr Val Val Ala
100 105 110GCA CCG GAA CAC GAA ACC AGC CGA GCC TAT ATT GAA TTA GCG GCA AAA 384Ala Pro Glu His Glu Thr Ser Arg Ala Tyr Ile Glu Leu Ala Ala Lys
115 120 125GTC GCT TCG GAA TTA TAC TGG CAA GGT TCG GTT ATC CCG TCT GAA ATT 432Val Ala Ser Glu Leu Tyr Trp Gln Gly Ser Val Ile Pro Ser Glu Ile
130 135 140ATG ATT CGT GAA GTA AAA TAA GTTTTAATAA CCACGAAAAC ACAAAGAACA 483Met Ile Arg Glu Val Lys *145 150CAAGCGGTAG AATTTGCAGA AAAATTTGCA AATCCTACCG CTTTTTTATT AGTACGATTC 543GCTGTTGGAC TGCTATTTGA TTTGGTTTGT CAGGATATTA TGTTATTGTA ATGAAATGTT 603AGTGAATTAT TTTTATTAAT TTGAAAGGAA ACAAAATGAA AATAAAAAAA CGTTACATTG 663CGCTGTTGGT CTTAGGTGTC GTTATCAGCT ATGCCTGGTA TCAAAATTAT CAATGGGAAC 723AGCTGATGTT AAGCGGTTAT TGTGAAAAGG ACGGAAGTTA TTTTGATGAT AGGCATACGA 783AGCAAGAACT GATTGATAGG GCAATTAACT ATATGCTGGA GCATCAATCT AAAAAAACAT 843ACGATGCTTA TACTGATGAA CCTTTAGAAA TAAAACCATA TTTAACAATA GAGGAATTTA 903AAAAACTCAA TCCAAATTGT TGTGAAATTA CCTCATGGCC AGCAGATGCA GTTCCACAAG 963ATTGGGATGT TCGTGTGGAA GGTAAGGCAT ATAGGTATGT AATCGTAAAA TATTTAAGAA 1023CCTTAGCAAA TAGAGAACCT GAACGATGGG AAACTAGTAT TGTTTTTGAT AATTGCGGCA 1083ATCCTAAAAG AGCAAGCTAC TTATATTATT TAAAGAGAGA AATTTATT ATG ACA AAA 1140
Met Thr Lys
1TTA ACT ATG CAA GAT GTG ACC AAT TTA TAT TTA TAT AAA ACG AAA ACT 1188Leu Thr Met Gln Asp Val Thr Asn Leu Tyr Leu Tyr Lys Thr Lys Thr
5 10 15CTA CCT AAA GAT AGA TTG GAT GAT TCA CTT ATT TCT GAA ATA GGA AAA 1236Leu Pro Lys Asp Arg Leu Asp Asp Ser Leu Ile Ser Glu Ile Gly Lys20 25 30 35GGA GAT GAT GAT ATT GAT AGA AAA GAA TTT ATG GTG GGG CCG GGA CGT 1284Gly Asp Asp Asp Ile Asp Arg Lys Glu Phe Met Val Gly Pro Gly Arg
40 45 50TTT GTG ACC GCT GAT AAC TTT AGC GTT GTA AGA GAT TTT TTT AAT GCT 1332Phe Val Thr Ala Asp Asn Phe Ser Val Val Arg Asp Phe Phe Asn Ala
55 60 65GGG AAA TCA CGC ATT ATT GCG CCG CAA GTC CCG CCT ATT CGT TCA CAG 1380Gly Lys Ser Arg Ile Ile Ala Pro Gln Val Pro Pro Ile Arg Ser Gln
70 75 80CAG GAA AAA ATC TTG GTC GGT TTA AAA CCG GGC AAA TAT TCC AAA GCG 1428Gln Glu Lys Ile Leu Val Gly Leu Lys Pro Gly Lys Tyr Ser Lys Ala
85 90 95CAG ATA TTG GAA ATG CTG GGT TAT ACG AAA GGC GGA GAA GTG GTA AAT 1476Gln Ile Leu Glu Met Leu Gly Tyr Thr Lys Gly Gly Glu Val Val Asn100 105 110 115GGC ATG TTT GCC GGT GAA GTC CAG ACA TTA GGC TTT TAT GAC GAT GGC 1524Gly Met Phe Ala Gly Glu Val Gln Thr Leu Gly Phe Tyr Asp Asp Gly
120 125 130AAA GGG GAT TTA CTC GAA CGC GCC TAT ATC TGG AAT ACC ACA GGA TTT 1572Lys Gly Asp Leu Leu Glu Arg Ala Tyr Ile Trp Asn Thr Thr Gly Phe
135 140 145AAA ATG AGC GAC AAT GCC TTT TTT GTT ATA GAA GAA TCA GGC AAA CGC 1620Lys Met Ser Asp Asn Ala Phe Phe Val Ile Glu Glu Ser Gly Lys Arg
150 155 160TAT ATT GAA AAC TTT GGT ATT GAA CCT CTT GGT AAG CAA GAA GAT TTT 1668Tyr Ile Glu Asn Phe Gly Ile Glu Pro Leu Gly Lys Gln Glu Asp Phe
165 170 175GAT TTT GTC GGC GGC TTT TGG TCT AAC TTA GTG AAT CGT GGT TTG GAA 1716Asp Phe Val Gly Gly Phe Trp Ser Asn Leu Val Asn Arg Gly Leu Glu180 185 190 195AGT ATT ATC GAC CCA TCC GGT ATC GGT GGA ACG GTA AAC CTT AAC TTT 1764Ser Ile Ile Asp Pro Ser Gly Ile Gly Gly Thr Val Asn Leu Asn Phe
200 205 210ACC GGC GAG GTG GAA ACC TAC ACG TTA GAC GAA ACA AGG TTT AAA GCG 1812Thr Gly Glu Val Glu Thr Tyr Thr Leu Asp Glu Thr Arg Phe Lys Ala
215 220 225GAA GCG GCG AAG AAA AGC CAT TGG AGT TTA GTG AAT GCG GCG AAA GTA 1860Glu Ala Ala Lys Lys Ser His Trp Ser Leu Val Asn Ala Ala Lys Val
230 235 240TAC GGC GGT TTA GAC CAA ATT ATT AAA AAA CTA TGG GAC AGT GGC TCA 1908Tyr Gly Gly Leu Asp Gln Ile Ile Lys Lys Leu Trp Asp Ser Gly Ser
245 250 255ATT AAG CAT TTA TAT CAA GAT AAA GAT ACG GGC AAA TTA AAA CCG ATT 1956Ile Lys His Leu Tyr Gln Asp Lys Asp Thr Gly Lys Leu Lys Pro Ile260 265 270 275ATT TAC GGC ACG GCC GGC AAC GAC AGT AAG ATT GAA GGC ACT AAA ATC 2004Ile Tyr Gly Thr Ala Gly Asn Asp Ser Lys Ile Glu Gly Thr Lys Ile
280 285 290ACC CGT AGG ATT GCG GGT AAA GAA GTT ACG CTT GAT ATT GCC AAT CAG 2052Thr Arg Arg Ile Ala Gly Lys Glu Val Thr Leu Asp Ile Ala Asn Gln
295 300 305AAA ATT GAA AAA GGC GTG TTA GAG AAA TTG GGG CTG TCT GTT AGT GGT 2100Lys Ile Glu Lys Gly Val Leu Glu Lys Leu Gly Leu Ser Val Ser Gly
310 315 320TCG GAT ATC ATT AAA TTG TTG TTT GGA GCA TTG ACT CCA ACT TTA AAT 2148Ser Asp Ile Ile Lys Leu Leu Phe Gly Ala Leu Thr Pro Thr Leu Asn
325 330 335AGA ATG TTG CTA TCA CAA CTT ATC CAG TCT TTT TCC GAT AGC TTG GCT 2196Arg Met Leu Leu Ser Gln Leu Ile Gln Ser Phe Ser Asp Ser Leu Ala340 345 350 355AAA CTT GAT AAT CCC TTA GCC CCT TAC ACT AAA AAT GGC GTG GTT TAT 2244Lys Leu Asp Asn Pro Leu Ala Pro Tyr Thr Lys Asn Gly Val Val Tyr
360 365 370GTC ACC GGC AAA GGG AAT GAT GTG CTT AAA GGA ACT GAA CAT GAG GAT 2292Val Thr Gly Lys Gly Asn Asp Val Leu Lys Gly Thr Glu His Glu Asp
375 380 385TTG TTT CTC GGT GGT GAG GGG AAT GAT ACT TAT TAT GCG AGA GTA GGC 2340Leu Phe Leu Gly Gly Glu Gly Asn Asp Thr Tyr Tyr Ala Arg Val Gly
390 395 400GAT ACA ATT GAA GAC GCC GAC GGC AAA GGT AAA GTC TAT TTT GTG AGA 2388Asp Thr Ile Glu Asp Ala Asp Gly Lys Gly Lys Val Tyr Phe Val Arg
405 410 415GAA AAA GGG GTA CCT AAG GCG GAT CCT AAG CGG GTA GAG TTT AGC GAG 2436Glu Lys Gly Val Pro Lys Ala Asp Pro Lys Arg Val Glu Phe Ser Glu420 425 430 435TAC ATA ACG AAA GAA GAA ATA AAA GAG GTT GAA AAG GGG TTA TTA ACT 2484Tyr Ile Thr Lys Glu Glu Ile Lys Glu Val Glu Lys Gly Leu Leu Thr
440 445 450TAC GCA GTT TTA GAA AAT TAT AAT TGG GAA GAG AAA ACG GCG ACT TTC 2532Tyr Ala Val Leu Glu Asn Tyr Asn Trp Glu Glu Lys Thr Ala Thr Phe
455 460 465GCT CAT GCG ACT ATG CTT AAT GAG CTT TTT ACT GAT TAT ACT AAT TAT 2580Ala His Ala Thr Met Leu Asn Glu Leu Phe Thr Asp Tyr Thr Asn Tyr
470 475 480CGT TAT GAA GTT AAA GGA CTA AAA TTG CCC GCC GTT AAA AAG TTA AAA 2628Arg Tyr Glu Val Lys Gly Leu Lys Leu Pro Ala Val Lys Lys Leu Lys
485 490 495AGT CCG TTG GTG GAG TTT ACA GCT GAT TTA TTA ACT GTT ACG CCT ATT 2676Ser Pro Leu Val Glu Phe Thr Ala Asp Leu Leu Thr Val Thr Pro Ile500 505 510 515GAC GAA AAC GGA AAA GCA CTT AGC GAA AAA AGT ATT ACG GTT AAA AAT 2724Asp Glu Asn Gly Lys Ala Leu Ser Glu Lys Ser Ile Thr Val Lys Asn
520 525 530TTT AAA AAT GGT GAT TTA GGA ATA AGG TTG TTG GAT CCT AAT AGC TAT 2772Phe Lys Asn Gly Asp Leu Gly Ile Arg Leu Leu Asp Pro Asn Ser Tyr
535 540 545TAT TAT TTC CTT GAA GGC CAA GAT ACG GGT TTT TAT GGT CCT GCT TTT 2820Tyr Tyr Phe Leu Glu Gly Gln Asp Thr Gly Phe Tyr Gly Pro Ala Phe
550 555 560TAT ATT GAA CGA AAA AAC GGT GGC GGC GCT AAA AAT AAC TCG TCG GGA 2868Tyr Ile Glu Arg Lys Asn Gly Gly Gly Ala Lys Asn Asn Ser Ser Gly
565 570 575GCA GGA AAT AGC AAA GAT TGG GGC GGG AAC GGG CAT GGA AAT CAC CGA 2916Ala Gly Asn Ser Lys Asp Trp Gly Gly Asn Gly His Gly Asn His Arg580 585 590 595AAT AAT GCC TCC GAC CTG AAT AAA CCG GAC GGA AAT AAT GGG AAT AAC 2964Asn Asn Ala Ser Asp Leu Asn Lys Pro Asp Gly Asn Asn Gly Asn Asn
600 605 610CAA AAT AAC GGA AGC AAT CAA GAT AAT CAT AGC GAT GTG AAT GCG CCA 3012Gln Asn Asn Gly Ser Asn Gln Asp Asn His Ser Asp Val Asn Ala Pro
615 620 625AAT AAC CCG GGA CGT AAC TAT GAT ATT TAC GAT CCT TTA GCT TTA GAT 3060Asn Asn Pro Gly Arg Asn Tyr Asp Ile Tyr Asp Pro Leu Ala Leu Asp
630 635 640TTA GAT GGA GAT GGG CTT GAA ACC GTG TCG ATG AAC GGG CGA CAA GGC 3108Leu Asp Gly Asp Gly Leu Glu Thr Val Ser Met Asn Gly Arg Gln Gly
645 650 655GCG TTA TTC GAT CAT GAA GGA AAA GGT ATT CGT ACC GCA ACG GGC TGG 3156Ala Leu Phe Asp His Glu Gly Lys Gly Ile Arg Thr Ala Thr Gly Trp660 665 670 675CTC GCT GCG GAT GAC GGT TTT TTA GTG TTA GAT CGT AAC CAA GAC GGC 3204Leu Ala Ala Asp Asp Gly Phe Leu Val Leu Asp Arg Asn Gln Asp Gly
680 685 690ATT ATT AAT GAT ATA AGC GAG TTA TTT AGT AAT AAA AAT CAA CTT TCC 3252Ile Ile Asn Asp Ile Ser Glu Leu Phe Ser Asn Lys Asn Gln Leu Ser
695 700 705GAC GGC AGT ATT TCT GCA CAC GGT TTT GCG ACA TTA GCC GAT TTG GAT 3300Asp Gly Ser Ile Ser Ala His Gly Phe Ala Thr Leu Ala Asp Leu Asp
710 715 720ACA AAC CAA GAT CAG CGT ATC GAC CAA AAT GAT AAG CTG TTT TCT AAA 3348Thr Asn Gln Asp Gln Arg Ile Asp Gln Asn Asp Lys Leu Phe Ser Lys
725 730 735CTC CAA ATT TGG CGG GAT TTA AAT CAA AAC GGT TTT AGT GAA GCG AAT 3396Leu Gln Ile Trp Arg Asp Leu Asn Gln Asn Gly Phe Ser Glu Ala Asn740 745 750 755GAG CTG TTT AGC TTA GAA AGT TTG AAT ATT AAA TCT TTA CAT ACC GCC 3444Glu Leu Phe Ser Leu Glu Ser Leu Asn Ile Lys Ser Leu His Thr Ala
760 765 770TAT GAA GAG CGT AAT GAT TTT CTA GCG GGC AAT AAT ATC CTT GCT CAG 3492Tyr Glu Glu Arg Asn Asp Phe Leu Ala Gly Asn Asn Ile Leu Ala Gln
775 780 785CTT GGG AAG TAT GAA AAA ACG GAC GGT ACT TTT GCA CAA ATG GGC GAT 3540Leu Gly Lys Tyr Glu Lys Thr Asp Gly Thr Phe Ala Gln Met Gly Asp
790 795 800TTA AAT TTC AGT TTT AAC CCG TTT TAT AGC CGA TTT ACC GAA GCG TTA 3588Leu Asn Phe Ser Phe Asn Pro Phe Tyr Ser Arg Phe Thr Glu Ala Leu
805 810 815AAT TTA ACC GAG CAA CAA CGT CGC ACA ATT AAT CTA ACC GGC ACC GGT 3636Asn Leu Thr Glu Gln Gln Arg Arg Thr Ile Asn Leu Thr Gly Thr Gly820 825 830 835CGG GTT CGG GAT TTG CGT GAA GCC GCC GCA CTT TCT GAG GAG TTG GCT 3684Arg Val Arg Asp Leu Arg Glu Ala Ala Ala Leu Ser Glu Glu Leu Ala
840 845 850GCT TTA TTA CAA CAG TAC ACT AAG GCC TCC GAT TTT CAG GCA CAA CGA 3732Ala Leu Leu Gln Gln Tyr Thr Lys Ala Ser Asp Phe Gln Ala Gln Arg
855 860 865GAA TTA TTG CCT GCC ATT TTA GAT AAA TGG GCG GCA ACG GAT TTA CAG 3780Glu Leu Leu Pro Ala Ile Leu Asp Lys Trp Ala Ala Thr Asp Leu Gln
870 875 880TAT CAA CAT TAT GAT AAA ACA TTA CTT AAA ACG GTA GAA AGT ACC GAT 3828Tyr Gln His Tyr Asp Lys Thr Leu Leu Lys Thr Val Glu Ser Thr Asp
885 890 895AGT AGT GCT TCT GTC GTT AGA GTC ACG CCT TCT CAA TTA AGT AGT ATA 3876Ser Ser Ala Ser Val Val Arg Val Thr Pro Ser Gln Leu Ser Ser Ile900 905 910 915CGC AAT GCA AAG CAT GAT CCT ACC GTT ATG CAA AAC TTT GAA CAG AGT 3924Arg Asn Ala Lys His Asp Pro Thr Val Met Gln Asn Phe Glu Gln Ser
920 925 930AAG GCA AAA ATT GCG ACT TTA AAT TCG CTC TAC GGG TTA AAT ATC GAT 3972Lys Ala Lys Ile Ala Thr Leu Asn Ser Leu Tyr Gly Leu Asn Ile Asp
935 940 945CAA CTT TAT TAC ACG ACG GAT AAA GAC ATT CGC TAT ATT ACT GAT AAA 4020Gln Leu Tyr Tyr Thr Thr Asp Lys Asp Ile Arg Tyr Ile Thr Asp Lys
950 955 960GTG AAT AAT ATG TAT CAA ACA ACC GTA GAA CTT GCC TAC CGT TCT TTA 4068Val Asn Asn Met Tyr Gln Thr Thr Val Glu Leu Ala Tyr Arg Ser Leu
965 970 975CTT TTA CAA ACG CGT TTG AAG AAA TAT GTT TAT AGC GTT AAT GCG AAA 4116Leu Leu Gln Thr Arg Leu Lys Lys Tyr Val Tyr Ser Val Asn Ala Lys980 985 990 995CAA TTC GAA GGG AAA TGG GTA ACC GAT TAT TCT CGT ACT GAA GCC TTA 4164Gln Phe Glu Gly Lys Trp Val Thr Asp Tyr Ser Arg Thr Glu Ala Leu
1000 1005 1010TTT AAC TCT ACT TTT AAA CAA TCG CCT GAA AAT GCA TTA TAT GAT TTA 4212Phe Asn Ser Thr Phe Lys Gln Ser Pro Glu Asn Ala Leu Tyr Asp Leu
1015 1020 1025AGC GAA TAC CTT TCT TTC TTT AAC GAT CCT ACG GAA TGG AAA GAA GGG 4260Ser Glu Tyr Leu Ser Phe Phe Asn Asp Pro Thr Glu Trp Lys Glu Gly
1030 1035 1040CTA TTA CTG TTA AGC CGT TAT ATA GAT TAT GCT AAA GCA CAA GGA TTT 4308Leu Leu Leu Leu Ser Arg Tyr Ile Asp Tyr Ala Lys Ala Gln Gly Phe
1045 1050 1055TAT GAA AAC TGG GCG GCT ACT TCT AAC TTA ACT ATT GCC CGT TTA AGA 4356Tyr Glu Asn Trp Ala Ala Thr Ser Asn Leu Thr Ile Ala Arg Leu Arg1060 1065 1070 1075GAG GCT GGA GTA ATT TTT GCA GAA TCG ACG GAT TTA AAA GGC GAT GAA 4404Glu Ala Gly Val Ile Phe Ala Glu Ser Thr Asp Leu Lys Gly Asp Glu
1080 1085 1090AAA AAT AAT ATT TTG TTA GGT AGC CAA AAA GAT AAT AAC TTA TCG GGT 4452Lys Asn Asn Ile Leu Leu Gly Sar Gln Lys Asp Asn Asn Leu Ser Gly
1095 1100 1105AGT GCA GGT GAT GAT CTA CTT ATC GGC GGA GAG GGT AAT GAT ACG TTA 4500Ser Ala Gly Asp Asp Leu Leu Ile Gly Gly Glu Gly Asn Asp Thr Leu
1110 1115 1120AAA GGC AGC TAC GGT GCA GAC ACC TAT ATC TTT AGC AAA GGA CAC GGA 4548Lys Gly Ser Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly His Gly
1125 1130 1135CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT GAT AAC CGC GCA AGA GAT 4596Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg Ala Arg Asp1140 1145 1150 1155ATC GAC ACC TTA AAA TTT ACC GAT GTG AAT TAT GCG GAA GTG AAG TTT 4644Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu Val Lys Phe
1160 1165 1170CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC GGT TAT CAT GAT ACG GAT 4692Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp Thr Asp
1175 1180 1185TCG GTC ACG GTA AAA TCC TTC TAC AGC CAT GTA GAT TAT CAA TTT GAC 4740Ser Val Thr Val Lys Ser Phe Tyr Ser His Val Asp Tyr Gln Phe Asn
1190 1195 1200AAA TTG GAG TTT GCT GAC CGC AGT ATA ACT CGC GAT GAA CTG ATT AAA 4788Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu Ile Lys
1205 1210 1215GCA GGG CTT CAT CTA TAC GGC ACC GAT GGC AAT GAT GAT ATA AAG GAT 4836Ala Gly Leu His Leu Tyr Gly Thr Asp Gly Asn Asp Asp Ile Lys Asp1220 1225 1230 1235CAT GCG GAT TGG GAC AGC ATT TTG GAA GGC GGC AAA GGC AAC GAT ATT 4884His Ala Asp Trp Asp Ser Ile Leu Glu Gly Gly Lys Gly Asn Asp Ile
1240 1245 1250CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT ATC TTT AGC AAA GGA CAC 4932Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys Gly His
1255 1260 1265GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT GAT AAC CGC GCA AGA 4980Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg Ala Arg
1270 1275 1280GAT ATC GAC ACC TTA AAA TTT ACT GAT GTG AAT TAT GCG GAA GTG AAA 5028Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu Val Lys
1285 1290 1295TTC CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC GGT TAT CAT GAT ACG 5076Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His Asp Thr1300 1305 1310 1315GAT TCG GTC ACG ATA AAA TCC TTC TAC AAC CAT GTA GAT TAT CAA TTT 5124Asp Ser Val Thr Ile Lys Ser Phe Tyr Asn His Val Asp Tyr Gln Phe
1320 1325 1330GAC AAA TTG GAA TTT GCT GAC CGC AGT ATA ACT CGT GAT GAA CTA GGT 5172Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu Leu Gly
1335 1340 1345AAA CAA GGT ATG GCA TTA TTT GGC ACT GAC GGT GAT GAT AAT ATC AAC 5220Lys Gln Gly Met Ala Leu Phe Gly Thr Asp Gly Asp Asp Asn Ile Asn
1350 1355 1360GAC TGG GGA CGT AAC TCG GTG ATT GAT GCC GGT GCG GGT AAT GAT ACG 5268Asp Trp Gly Arg Asn Ser Val Ile Asp Ala Gly Ala Gly Asn Asp Thr
1365 1370 1375GTT AAT GGC GGT AAT GGC GAT GAC ACC CTC ATC GGC GGC AAA GGT AAT 5316Val Asn Gly Gly Asn Gly Asp Asp Thr Leu Ile Gly Gly Lys Gly Asn1380 1385 1390 1395GAT ATT CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT ATC TTT AGC AAA 5364Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys
1400 1405 1410GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT GAT AAC CGC 5412Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg
1415 1420 1425GCA AGA GAT ATC GAC ACC TTA AAA TTT ACC GAT GTG AAT TAT GCG GAA 5460Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu
1430 1435 1440GTG AAA TTC CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC GGT TAT CAT 5508Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His
1445 1450 1455GAT ACG GAT TCG GTC ACG GTA AAA TCC TTC TAC AGC CAT GTA GAT TAT 5556Asp Thr Asp Ser Val Thr Val Lys Ser Phe Tyr Ser His Val Asp Tyr1460 1465 1470 1475CAA TTT GAC AAA TTG GAG TTT GCT GAC CGC AGT ATA ACT CGC GAT GAA 5604Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu
1480 1485 1490CTG ATT AAA GCA GGG CTT CAT CTA TAC GGC ACC GAT GGC AAT GAT GAT 5652Leu Ile Lys Ala Gly Leu His Leu Tyr Gly Thr Asp Gly Asn Asp Asp
1495 1500 1505ATA AAG GAT CAT GCG GAT TGG GAC AGC ATT TTG GAA GGC GGC AAA GGC 5700Ile Lys Asp His Ala Asp Trp Asp Ser Ile Leu Glu Gly Gly Lys Gly
1510 1515 1520AAC GAT ATT CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT ATC TTT AGC 5748Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser
1525 1530 1535AAA GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT GAT AAC 5796Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn1540 1545 1550 1555CGA GCA AGA GAT ATC GAC ACC TTA AAA TTT ACT GAT GTG AAT TAT GCG 5844Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala
1560 1565 1570GAA GTG AAA TTC CGA CGA GTA GAT AAT GAC TTA ATG TTA TTC GGT TAT 5892Glu Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr
1575 1580 1585CAT GAT ACG GAT TCG GTC ACG ATA AAA TCC TTC TAC AAC CAT GTA GAT 5940His Asp Thr Asp Ser Val Thr Ile Lys Ser Phe Tyr Asn His Val Asp
1590 1595 1600TAT CAA TTT GAC AAA TTG GAA TTT GCT GAC CGC AGT ATA ACT CGT GAT 5988Tyr Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp
1605 1610 1615GAA CTA GGT AAA CAA GGT ATG GCA TTA TTT GGC ACT GAC GGT GAT GAT 6036Glu Leu Gly Lys Gln Gly Met Ala Leu Phe Gly Thr Asp Gly Asp Asp1620 1625 1630 1635AAT ATC AAC GAC TGG GGA CGT AAC TCG GTG ATT GAT GCC GGT GCG GGT 6084Asn Ile Asn Asp Trp Gly Arg Asn Ser Val Ile Asp Ala Gly Ala Gly
1640 1645 1650AAT GAT ACG GTT AAT GGC GGT AAT GGC GAT GAC ACC CTC ATC GGC GGC 6132Asn Asp Thr Val Asn Gly Gly Asn Gly Asp Asp Thr Leu Ile Gly Gly
1655 1660 1665AAA GGT AAT GAT ATT CTA AGA GGT GGC TAC GGT GCG GAC ACC TAT ATC 6180Lys Gly Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile
1670 1675 1680TTT AGC AAA GGA CAC GGA CAG GAT ATC GTT TAT GAA GAT ACC AAT AAT 6228Phe Ser Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn
1685 1690 1695GAT AAC CGC GCA AGA GAT ATC GAC ACC TTA AAA TTT ACT GAT ATT AAT 6276Asp Asn Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Ile Asn1700 1705 1710 1715TTA TCC GAA CTT TGG TTT AGC CGA GAA AAT AAC GAT TTG ATT ATT AAA 6324Leu Ser Glu Leu Trp Phe Ser Arg Glu Asn Asn Asp Leu Ile Ile Lys
1720 1725 1730TCA TTA TTA AGT GAG GAT AAA GTC ACG GTT CAA AAT TGG TAT TCA CAC 6372Ser Leu Leu Ser Glu Asp Lys Val Thr Val Gln Asn Trp Tyr Ser His
1735 1740 1745CAA GAT CAT AAA ATA GAA AAT ATT CGT TTA TCG AAT GAG CAA ACG TTG 6420Gln Asp His Lys Ile Glu Asn Ile Arg Leu Ser Asn Glu Gln Thr Leu
1750 1755 1760GTG AGC ACT CAG GTG GAG AAG ATG GTT GAG TCG ATG GCC GGC TTT GCT 6468Val Ser Thr Gln Val Glu Lys Met Val Glu Ser Met Ala Gly Phe Ala
1765 1770 1775CAG AAG CAC GGA GGA GAG ATA TCT CTT GTG TCG CTT GAA GAG GTA AAA 6516Gln Lys His Gly Gly Glu Ile Ser Leu Val Ser Leu Glu Glu Val Lys1780 1785 1790 1795CAA TAT ATC AAT AGC TTA ACA GCT GCT TTA TAA CATACGAAAG AAATCGGCAC 6569Gln Tyr Ile Asn Ser Leu Thr Ala Ala Leu *
1800 1805AGTTTTTTTG AACTGTGCCG ATTTGATTTT AGTGTAAGAA TATAGCCTGA TTTTAAGAAA 6629TTTACTCTTG GCTAATAACT ATTTCCCATT TTATAAGTTA TTGACGGATG GTTTTATCAA 6689ATATGAGATC AAATCTTATT TTAAATTCGC TTTCCATTAA GCGATAT 6736(2)SEQ ID NO:6信息:
(i)序列特征:
(A)长度:151个氨基酸
(B)类型:氨基酸
(D)拓扑学:线性
(ii)分子类型:蛋白
(xi)序列描述:SEQ ID NO:6:Ile Asp Met Pro Pro Gly Thr Gly Asp Ile Gln Leu Thr Leu Ser Gln1 5 10 15Gln Ile Pro Val Thr Gly Ala Val Val Val Thr Thr Pro Gln Asp Ile
20 25 30Ala Leu Leu Asp Ala Val Lys Gly Ile Ser Met Phe Gln Lys Val Ser
35 40 45Val Pro Val Leu Gly Ile Ile Glu Asn Met Ser Val His Ile Cys Gln
50 55 60Asn Cys Gly His His Glu Asp Ile Phe Gly Thr Gly Gly Ala Glu Lys65 70 75 80Val Ala Lys Lys Tyr Gly Thr Lys Val Leu Gly Gln Met Pro Leu His
85 90 95Ile Arg Leu Arg Gln Asp Leu Asp Ala Gly Thr Pro Thr Val Val Ala
100 105 110Ala Pro Glu His Glu Thr Ser Arg Ala Tyr Ile Glu Leu Ala Ala Lys
115 120 125Val Ala Ser Glu Leu Tyr Trp Gln Gly Ser Val Ile Pro Ser Glu Ile
130 135 140Met Ile Arg Glu Val Lys *145 150(2)SEQ ID NO:7信息:
(i)序列特征:
(A)长度:1806个氨基酸
(B)类型:氨基酸
(D)拓扑学:线性
(ii)分子类型:蛋白
(xi)序列描述:SEQ ID NO:7:Met Thr Lys Leu Thr Met Gln Asp Val Thr Asn Leu Tyr Leu Tyr Lys1 5 10 15Thr Lys Thr Leu Pro Lys Asp Arg Leu Asp Asp Ser Leu Ile Ser Glu
20 25 30Ile Gly Lys Gly Asp Asp Asp Ile Asp Arg Lys Glu Phe Met Val Gly
35 40 45Pro Gly Arg Phe Val Thr Ala Asp Asn Phe Ser Val Val Arg Asp Phe
50 55 60Phe Asn Ala Gly Lys Ser Arg Ile Ile Ala Pro Gln Val Pro Pro Ile65 70 75 80Arg Ser Gln Gln Glu Lys Ile Leu Val Gly Leu Lys Pro Gly Lys Tyr
85 90 95Ser Lys Ala Gln Ile Leu Glu Met Leu Gly Tyr Thr Lys Gly Gly Glu
100 105 110Val Val Asn Gly Met Phe Ala Gly Glu Val Gln Thr Leu Gly Phe Tyr
115 120 125Asp Asp Gly Lys Gly Asp Leu Leu Glu Arg Ala Tyr Ile Trp Asn Thr
130 135 140Thr Gly Phe Lys Met Ser Asp Asn Ala Phe Phe Val Ile Glu Glu Ser145 150 155 160Gly Lys Arg Tyr Ile Glu Asn Phe Gly Ile Glu Pro Leu Gly Lys Gln
165 170 175Glu Asp Phe Asp Phe Val Gly Gly Phe Trp Ser Asn Leu Val Asn Arg
180 185 190Gly Leu Glu Ser Ile Ile Asp Pro Ser Gly Ile Gly Gly Thr Val Asn
195 200 205Leu Asn Phe Thr Gly Glu Val Glu Thr Tyr Thr Leu Asp Glu Thr Arg
210 215 220Phe Lys Ala Glu Ala Ala Lys Lys Ser His Trp Ser Leu Val Asn Ala225 230 235 240Ala Lys Val Tyr Gly Gly Leu Asp Gln Ile Ile Lys Lys Leu Trp Asp
245 250 255Ser Gly Ser Ile Lys His Leu Tyr Gln Asp Lys Asp Thr Gly Lys Leu
260 265 270Lys Pro Ile Ile Tyr Gly Thr Ala Gly Asn Asp Ser Lys Ile Glu Gly
275 280 285Thr Lys Ile Thr Arg Arg Ile Ala Gly Lys Glu Val Thr Leu Asp Ile
290 295 300Ala Asn Gln Lys Ile Glu Lys Gly Val Leu Glu Lys Leu Gly Leu Ser305 310 315 320Val Ser Gly Ser Asp Ile Ile Lys Leu Leu Phe Gly Ala Leu Thr Pro
325 330 335Thr Leu Asn Arg Met Leu Leu Ser Gln Leu Ile Gln Ser Phe Ser Asp
340 345 350Ser Leu Ala Lys Leu Asp Asn Pro Leu Ala Pro Tyr Thr Lys Asn Gly
355 360 365Val Val Tyr Val Thr Gly Lys Gly Asn Asp Val Leu Lys Gly Thr Glu
370 375 380His Glu Asp Leu Phe Leu Gly Gly Glu Gly Asn Asp Thr Tyr Tyr Ala385 390 395 400Arg Val Gly Asp Thr Ile Glu Asp Ala Asp Gly Lys Gly Lys Val Tyr
405 410 415Phe Val Arg Glu Lys Gly Val Pro Lys Ala Asp Pro Lys Arg Val Glu
420 425 430Phe Ser Glu Tyr Ile Thr Lys Glu Glu Ile Lys Glu Val Glu Lys Gly
435 440 445Leu Leu Thr Tyr Ala Val Leu Glu Asn Tyr Asn Trp Glu Glu Lys Thr
450 455 460Ala Thr Phe Ala His Ala Thr Met Leu Asn Glu Leu Phe Thr Asp Tyr465 470 475 480Thr Asn Tyr Arg Tyr Glu Val Lys Gly Leu Lys Leu Pro Ala Val Lys
485 490 495Lys Leu Lys Ser Pro Leu Val Glu Phe Thr Ala Asp Leu Leu Thr Val
500 505 510Thr Pro Ile Asp Glu Asn Gly Lys Ala Leu Ser Glu Lys Ser Ile Thr
515 520 525Val Lys Asn Phe Lys Asn Gly Asp Leu Gly Ile Arg Leu Leu Asp Pro
530 535 540Asn Ser Tyr Tyr Tyr Phe Leu Glu Gly Gln Asp Thr Gly Phe Tyr Gly545 550 555 560Pro Ala Phe Tyr Ile Glu Arg Lys Asn Gly Gly Gly Ala Lys Asn Asn
565 570 575Ser Ser Gly Ala Gly Asn Ser Lys Asp Trp Gly Gly Asn Gly His Gly
580 585 590Asn His Arg Asn Asn Ala Ser Asp Leu Asn Lys Pro Asp Gly Asn Asn
595 600 605Gly Asn Asn Gln Asn Asn Gly Ser Asn Gln Asp Asn His Ser Asp Val
610 615 620Asn Ala Pro Asn Asn Pro Gly Arg Asn Tyr Asp Ile Tyr Asp Pro Leu625 630 635 640Ala Leu Asp Leu Asp Gly Asp Gly Leu Glu Thr Val Ser Met Asn Gly
645 650 655Arg Gln Gly Ala Leu Phe Asp His Glu Gly Lys Gly Ile Arg Thr Ala
660 665 670Thr Gly Trp Leu Ala Ala Asp Asp Gly Phe Leu Val Leu Asp Arg Asn
675 680 685Gln Asp Gly Ile Ile Asn Asp Ile Ser Glu Leu Phe Ser Asn Lys Asn
690 695 700Gln Leu Ser Asp Gly Ser Ile Ser Ala His Gly Phe Ala Thr Leu Ala705 710 715 720Asp Leu Asp Thr Asn Gln Asp Gln Arg Ile Asp Gln Asn Asp Lys Leu
725 730 735Phe Ser Lys Leu Gln Ile Trp Arg Asp Leu Asn Gln Asn Gly Phe Ser
740 745 750Glu Ala Asn Glu Leu Phe Ser Leu Glu Ser Leu Asn Ile Lys Ser Leu
755 760 765His Thr Ala Tyr Glu Glu Arg Asn Asp Phe Leu Ala Gly Asn Asn Ile
770 775 780Leu Ala Gln Leu Gly Lys Tyr Glu Lys Thr Asp Gly Thr Phe Ala Gln785 790 795 800Met Gly Asp Leu Asn Phe Ser Phe Asn Pro Phe Tyr Ser Arg Phe Thr
805 810 815Glu Ala Leu Asn Leu Thr Glu Gln Gln Arg Arg Thr Ile Asn Leu Thr
820 825 830Gly Thr Gly Arg Val Arg Asp Leu Arg Glu Ala Ala Ala Leu Ser Glu
835 840 845Glu Leu Ala Ala Leu Leu Gln Gln Tyr Thr Lys Ala Ser Asp Phe Gln
850 855 860Ala Gln Arg Glu Leu Leu Pro Ala Ile Leu Asp Lys Trp Ala Ala Thr865 870 875 880Asp Leu Gln Tyr Gln His Tyr Asp Lys Thr Leu Leu Lys Thr Val Glu
885 890 895Ser Thr Asp Ser Ser Ala Ser Val Val Arg Val Thr Pro Ser Gln Leu
900 905 910Ser Ser Ile Arg Asn Ala Lys His Asp Pro Thr Val Met Gln Asn Phe
915 920 925Glu Gln Ser Lys Ala Lys Ile Ala Thr Leu Asn Ser Leu Tyr Gly Leu
930 935 940Asn Ile Asp Gln Leu Tyr Tyr Thr Thr Asp Lys Asp Ile Arg Tyr Ile945 950 955 960Thr Asp Lys Val Asn Asn Met Tyr Gln Thr Thr Val Glu Leu Ala Tyr
965 970 975Arg Ser Leu Leu Leu Gln Thr Arg Leu Lys Lys Tyr Val Tyr Ser Val
980 985 990Asn Ala Lys Gln Phe Glu Gly Lys Trp Val Thr Asp Tyr Ser Arg Thr
995 1000 1005Glu Ala Leu Phe Asn Ser Thr Phe Lys Gln Ser Pro Glu Asn Ala Leu
1010 1015 1020Tyr Asp Leu Ser Glu Tyr Leu Ser Phe Phe Asn Asp Pro Thr Glu Trp1025 1030 1035 1040Lys Glu Gly Leu Leu Leu Leu Ser Arg Tyr Ile Asp Tyr Ala Lys Ala
1045 1050 1055Gln Gly Phe Tyr Glu Asn Trp Ala Ala Thr Ser Asn Leu Thr Ile Ala
1060 1065 1070Arg Leu Arg Glu Ala Gly Val Ile Phe Ala Glu Ser Thr Asp Leu Lys
1075 1080 1085Gly Asp Glu Lys Asn Asn Ile Leu Leu Gly Ser Gln Lys Asp Asn Asn
1090 1095 1100Leu Ser Gly Ser Ala Gly Asp Asp Leu Leu Ile Gly Gly Glu Gly Asn1105 1110 1115 1120Asp Thr Leu Lys Gly Ser Tyr Gly Ala Asp Thr Tyr Ile Phe Ser Lys
1125 1130 1135Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn Arg
1140 1145 1150Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala Glu
1155 1160 1165Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr His
1170 1175 1180Asp Thr Asp Ser Val Thr Val Lys Ser Phe Tyr Ser His Val Asp Tyr1185 1190 1195 1200Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp Glu
1205 1210 1215Leu Ile Lys Ala Gly Leu His Leu Tyr Gly Thr Asp Gly Asn Asp Asp
1220 1225 1230Ile Lys Asp His Ala Asp Trp Asp Ser Ile Leu Glu Gly Gly Lys Gly
1235 1240 1245Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile Phe Ser
1250 1255 1260Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn Asp Asn1265 1270 1275 1280Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn Tyr Ala
1285 1290 1295Glu Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe Gly Tyr
1300 1305 1310His Asp Thr Asp Ser Val Thr Ile Lys Ser Phe Tyr Asn His Val Asp
1315 1320 1325Tyr Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr Arg Asp
1330 1335 1340Glu Leu Gly Lys Gln Gln Met Ala Leu Phe Gly Thr Asp Gly Asp Asp1345 1350 1355 1360Asn Ile Asn Asp Trp Gly Arg Asn Ser Val Ile Asp Ala Gly Ala Gly
1365 1370 1375Asn Asp Thr Val Asn Gly Gly Asn Gly Asp Asp Thr Leu Ile Gly Gly
1380 1385 1390Lys Gly Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr Ile
1395 1400 1405Phe Ser Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn Asn
1410 1415 1420Asp Asn Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val Asn1425 1430 1435 1440Tyr Ala Glu Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu Phe
1445 1450 1455Gly Tyr His Asp Thr Asp Ser Val Thr Val Lys Ser Phe Tyr Ser His
1460 1465 1470Val Asp Tyr Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile Thr
1475 1480 1485Arg Asp Glu Leu Ile Lys Ala Gly Leu His Leu Tyr Gly Thr Asp Gly
1490 1495 1500Asn Asp Asp Ile Lys Asp His Ala Asp Trp Asp Ser Ile Leu Glu Gly1505 1510 1515 1520Gly Lys Gly Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp Thr Tyr
1525 1530 1535Ile Phe Ser Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp Thr Asn
1540 1545 1550Asn Asp Asn Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr Asp Val
1555 1560 1565Asn Tyr Ala Glu Val Lys Phe Arg Arg Val Asp Asn Asp Leu Met Leu
1570 1575 1580Phe Gly Tyr His Asp Thr Asp Ser Val Thr Ile Lys Ser Phe Tyr Asn1585 1590 1595 1600His Val Asp Tyr Gln Phe Asp Lys Leu Glu Phe Ala Asp Arg Ser Ile
1605 1610 1615Thr Arg Asp Glu Leu Gly Lys Gln Gly Met Ala Leu Phe Gly Thr Asp
1620 1625 1630Gly Asp Asp Asn Ile Asn Asp Trp Gly Arg Asn Ser Val Ile Asp Ala
1635 1640 1645Gly Ala Gly Asn Asp Thr Val Asn Gly Gly Asn Gly Asp Asp Thr Leu
1650 1655 1660Ile Gly Gly Lys Gly Asn Asp Ile Leu Arg Gly Gly Tyr Gly Ala Asp1665 1670 1675 1680Thr Tyr Ile Phe Ser Lys Gly His Gly Gln Asp Ile Val Tyr Glu Asp
1685 1690 1695Thr Asn Asn Asp Asn Arg Ala Arg Asp Ile Asp Thr Leu Lys Phe Thr
1700 1705 1710Asp Ile Asn Leu Ser Glu Leu Trp Phe Ser Arg Glu Asn Asn Asp Leu
1715 1720 1725Ile Ile Lys Ser Leu Leu Ser Glu Asp Lys Val Thr Val Gln Asn Trp
1730 1735 1740Tyr Ser His Gln Asp His Lys Ile Glu Asn Ile Arg Leu Ser Asn Glu1745 1750 1755 1760Gln Thr Leu Val Ser Thr Gln Val Glu Lys Met Val Glu Ser Met Ala
1765 1770 1775Gly Phe Ala Gln Lys His Gly Gly Glu Ile Ser Leu Val Ser Leu Glu
1780 1785 1790Glu Val Lys Gln Tyr Ile Asn Ser Leu Thr Ala Ala Leu *
1795 1800 1805
Claims (22)
1.减毒的活胸膜肺炎放线杆菌,其特征在于所述的细菌产生无功能的ApxIV毒素。
2.根据权利要求1的活减毒菌,其特征在于编码ApxIV毒素的基因包括一个突变。
3.根据权利要求2的活减毒菌,其特征在于所述的突变为插入和/或缺失。
4.根据权利要求3的活减毒菌,其特征在于插入包括异源基因。
5.根据权利要求4的活减毒菌,其特征在于所述的异源基因编码一个或多个选自以下类群的抗原,包括猪生殖呼吸综合症(PRRS)病毒、假狂犬病病毒、猪流感病毒、猪细小病毒、传染性胃肠炎病毒、轮状病毒、大肠杆菌、猪丹毒丝菌、多杀巴斯德氏菌,支气管炎博德特氏菌、副猪嗜血杆菌和猪链球菌。
6.根据权利要求4或5的活减毒菌,其特征在于所述的异源基因有功能地连接到apxIV基因的启动子区域。
7.核苷酸序列,其中带有控制apxIV基因表达的启动子。
8.根据权利要求7的核苷酸序列,其特征在于其包括SEQ ID NO:5中位置451到1132的DNA片段或仍具有启动子活性的其子片段。
9.根据权利要求7的核苷酸序列,其特征在于其包括SEQ ID NO:5中位置617到641的DNA片段。
10.用于保护动物免受胸膜肺炎放线杆菌种类的细菌感染的亚单位疫苗,其特征在于所述的疫苗包括纯化的ApxIV毒素和药物上可接受的载体。
11.用于保护动物免受胸膜肺炎放线杆菌种类的细菌感染的活减毒疫苗,其特征在于所述的疫苗包括根据权利要求1-6的活减毒菌和药物上可接受的载体。
12.根据权利要求10或11的疫苗,特征在于其包括佐剂。
13.根据权利要求10-12的疫苗,特征在于该疫苗为冻干的形式。
14.根据权利要求10-13的疫苗,特征在于其额外包括一种或多种来自猪病原性微生物或病毒的抗原。
15.根据权利要求14的疫苗,特征在于其额外包括一种或多种选自以下类群的抗原,包括猪生殖呼吸综合症(PRRS)病毒、假狂犬病毒、猪流感病毒、猪细小病毒、传染性胃肠炎病毒、轮状病毒、大肠杆菌、猪丹毒丝菌、多杀巴斯德氏菌、支气管炎博德特氏菌、副猪嗜血杆菌及猪链球菌。
16.用于保护易感动物免受胸膜肺炎放线杆菌感染的方法,所述的方法包括施用根据权利要求10-15的疫苗。
17.用于制备产生无功能ApxIV毒素胸膜肺炎放线杆菌种类活减毒菌的方法,特征在于所述的方法包括在编码apxIV蛋白的基因中导入突变。
18.根据权利要求17的方法,特征在于所述的突变通过导入缺失而获得。
19.用于制备根据权利要求11-15活减毒疫苗的方法,所述的方法包括将根据权利要求1-6的细菌与药物上可接受的载体混合。
20.用于制备根据权利要求10疫苗的方法,所述的方法包括将纯化的ApxIV毒素与药物上可接受的载体混合。
21.诊断测试,其用于区分以胸膜肺炎放线杆菌野生菌株感染的猪血清与包括根据权利要求1活减毒胸膜肺炎放线杆菌菌株的疫苗接种的猪血清,所述的测试特征在于该测试包括纯化的ApxIV毒素。
22.用于区分猪中胸膜肺炎放线杆菌感染与猪中猪放线杆菌感染的诊断测试,特征在于所述的测试包括纯化的ApxIV毒素。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201032 | 1997-04-10 | ||
EP97201032.6 | 1997-04-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1202523A true CN1202523A (zh) | 1998-12-23 |
CN1198918C CN1198918C (zh) | 2005-04-27 |
Family
ID=8228185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB981098487A Expired - Lifetime CN1198918C (zh) | 1997-04-10 | 1998-04-09 | 减毒的活胸膜肺炎放线杆菌 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6013266A (zh) |
JP (1) | JPH10290695A (zh) |
KR (1) | KR100510906B1 (zh) |
CN (1) | CN1198918C (zh) |
AU (1) | AU743165B2 (zh) |
BR (1) | BR9801397A (zh) |
CA (1) | CA2228719A1 (zh) |
ES (1) | ES2443094T3 (zh) |
HU (1) | HUP9800855A3 (zh) |
NZ (1) | NZ330159A (zh) |
TW (2) | TW593678B (zh) |
ZA (1) | ZA982870B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112704732A (zh) * | 2020-12-24 | 2021-04-27 | 华中农业大学 | 一种猪传染性胸膜肺炎放线杆菌亚单位疫苗 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU769539B2 (en) * | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
GB0228691D0 (en) * | 2002-12-09 | 2003-01-15 | Imp College Innovations Ltd | Bacterial virulence genes |
WO2004078926A2 (en) * | 2003-02-28 | 2004-09-16 | Board Of Trustees Operating Michigan State University | Immunologigal markers |
US8637047B2 (en) * | 2003-10-30 | 2014-01-28 | Boehringer Ingelheim Vetmedica, Inc. | Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same |
MX2012005366A (es) * | 2009-11-10 | 2012-06-13 | Boehringer Ingelheim Vetmed | Antigenos de actinobacillus suis. |
ES2416154B1 (es) | 2011-11-09 | 2015-04-01 | Laboratorios Hipra, S.A. | Cepa viva atenuada de Actinobacillus pleuropneumoniae |
KR101491793B1 (ko) | 2013-09-10 | 2015-02-16 | 대한민국 | 신규한 액티노바실러스 플로르뉴모니아 혈청형 12번 균주, 이를 포함하는 진단용 조성물 및 백신 조성물 |
EP3062816B1 (en) | 2013-11-01 | 2020-08-05 | Boehringer Ingelheim Animal Health USA Inc. | Attenuated pasteurella multocida vaccines & methods of making & use thereof |
CN103777018A (zh) * | 2014-01-16 | 2014-05-07 | 江西农业大学 | 猪传染性胸膜肺炎放线杆菌快速诊断试纸条的制备方法 |
GB202011902D0 (en) * | 2020-07-30 | 2020-09-16 | Imperial College Innovations Ltd | Antinobacillus pleuropneumoniae vaccines |
-
1998
- 1998-04-03 ZA ZA982870A patent/ZA982870B/xx unknown
- 1998-04-08 BR BR9801397A patent/BR9801397A/pt not_active Application Discontinuation
- 1998-04-08 NZ NZ330159A patent/NZ330159A/xx unknown
- 1998-04-08 ES ES04077590.0T patent/ES2443094T3/es not_active Expired - Lifetime
- 1998-04-09 AU AU60781/98A patent/AU743165B2/en not_active Ceased
- 1998-04-09 KR KR1019980012518A patent/KR100510906B1/ko not_active IP Right Cessation
- 1998-04-09 CN CNB981098487A patent/CN1198918C/zh not_active Expired - Lifetime
- 1998-04-09 US US09/057,570 patent/US6013266A/en not_active Expired - Lifetime
- 1998-04-09 CA CA002228719A patent/CA2228719A1/en not_active Abandoned
- 1998-04-09 HU HU9800855A patent/HUP9800855A3/hu unknown
- 1998-04-10 JP JP10098877A patent/JPH10290695A/ja active Pending
- 1998-07-28 TW TW087112330A patent/TW593678B/zh not_active IP Right Cessation
- 1998-07-28 TW TW093112492A patent/TWI241407B/zh not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112704732A (zh) * | 2020-12-24 | 2021-04-27 | 华中农业大学 | 一种猪传染性胸膜肺炎放线杆菌亚单位疫苗 |
CN112704732B (zh) * | 2020-12-24 | 2022-02-25 | 华中农业大学 | 一种猪传染性胸膜肺炎放线杆菌亚单位疫苗 |
Also Published As
Publication number | Publication date |
---|---|
TW593678B (en) | 2004-06-21 |
HUP9800855A3 (en) | 2004-03-29 |
KR100510906B1 (ko) | 2006-01-12 |
NZ330159A (en) | 1998-10-28 |
BR9801397A (pt) | 1999-06-01 |
HUP9800855A2 (hu) | 1999-03-29 |
CA2228719A1 (en) | 1998-10-10 |
ES2443094T3 (es) | 2014-02-17 |
CN1198918C (zh) | 2005-04-27 |
TW200502384A (en) | 2005-01-16 |
US6013266A (en) | 2000-01-11 |
AU743165B2 (en) | 2002-01-17 |
ZA982870B (en) | 1998-10-09 |
AU6078198A (en) | 1998-10-15 |
TWI241407B (en) | 2005-10-11 |
KR19980081220A (ko) | 1998-11-25 |
HU9800855D0 (en) | 1998-07-28 |
JPH10290695A (ja) | 1998-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1201818C (zh) | 疫苗 | |
CN1145697C (zh) | 治疗和诊断组合物 | |
CN1284965A (zh) | 脑膜炎奈瑟氏球菌的新表面蛋白 | |
CN1184505A (zh) | 鼠疫疫苗 | |
CN1192241A (zh) | Hsp70家族的链球菌热休克蛋白 | |
CN1437653A (zh) | 抗原多肽 | |
CN1298848C (zh) | 具有减弱的蛋白酶活性的嗜血杆菌Hin47类似物 | |
CN1556857A (zh) | 呼吸道合胞病毒(rsv)g蛋白的新肽及其在疫苗中的应用 | |
CN101068567A (zh) | 嵌合噬菌体衍生的颗粒,它们的制造方法和用途 | |
CN1440419A (zh) | 治疗和预防细菌感染的化合物和方法 | |
CN1198918C (zh) | 减毒的活胸膜肺炎放线杆菌 | |
CN1294264C (zh) | 莫拉氏菌的高分子量的主要外膜蛋白质 | |
CN1798844A (zh) | Sars病毒抗原的细胞表面表达载体和用该载体转化的微生物 | |
CN1200763A (zh) | 来自幽门螺杆菌的新型粘附素 | |
CN1215167C (zh) | 幽门螺杆菌活疫苗 | |
CN1934240A (zh) | 减毒的革兰氏阴性细菌 | |
CN1245512C (zh) | 含重组菌毛蛋白的抗淋病奈瑟氏球茵或脑膜炎奈瑟氏球菌的疫苗 | |
CN1849334A (zh) | 胞内劳森氏菌亚单位疫苗 | |
CN1213402A (zh) | 表层蛋白的重组表达 | |
CN1653084A (zh) | 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体 | |
CN100347190C (zh) | 编码rpsL基因的核苷酸序列 | |
CN1894272A (zh) | 蛋白质表达 | |
CN1275164A (zh) | 奈瑟氏球菌乳铁蛋白结合蛋白 | |
CN1210401C (zh) | 源自粘膜炎莫拉氏菌的化合物 | |
CN1124339C (zh) | 新的细胞表面蛋白质 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: INTERVET INTERNATIONAL CO., LTD. Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP. Effective date: 20061208 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20061208 Address after: Holland Haier box Patentee after: Intervet International Co., Ltd. Address before: Holland Arnhem Patentee before: Akzo Nobel N. V. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050427 |